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Abstract
Two studies undertaken for the generation of catalytic antibodies with hydrolytic activity
are described. In the first study, heterologous immunization, where an animal is immunized in
succession with two different but structurally related hapten-protein conjugates, has been used to
induce antibody catalysts superior to those derived from homologous immunization with the
primary antigen. This heterologous immunization procedure offers two distinct advantages over
homologous immunization: (i) a means to introduce bi-functional catalytic residues into antibody
combining sites without recourse to a complex hapten synthesis, and (ii) the ability to screen an
expanded repertoire of antibody combining sites for catalysts. In the second study, three
structurally related haptens with a 1,2-amino alcohol functionality were designed and synthesized,
with the goal of generating esterolytic antibodies via homologous immunization. In order to begin
to understand rules for creating catalytic sites in antibodies, the studies were extensive in scope,
encompassing complete sets of catalytic and noncatalytic monoclonal antibodies. The
accompanying analysis provides information that is useful for the future development of catalytic
antibody technology.
Thesis Supervisor: Professor Satoru Masamune
Title: Professor of Chemistry
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Chapter 1
Introduction
In 1948, Linus Pauling postulated that the binding forces in both enzymes and antibodies
are fundamentally the same.la However, nature has dictated that an enzyme can catalyze a
chemical reaction, but an antibody cannot. This significant distinction is supposedly due to the fact
that an enzyme utilizes its binding energy to stabilize the transition state of a reaction, whereas an
antibody utilizes it to recognize the ground state of the molecule. This postulation implies that if
one had an antibody that specifically binds the transition state of a given chemical reaction, the
antibody might be able to catalyze that reaction.lb
With this in mind, in 1975 Raso and Stollar reported an attempt to use a small organic
molecule (a so-called hapten) conjugated with an appropriate carrier protein in order to generate
antibodies capable of catalyzing the condensation of pyridoxal-P and tyrosine (Scheme 1).2
Scheme 1 OH
NH-Carrier Protein
Hapten
OH
OH
H O O
NH2 2-0 3Po
Pyridoxal-P Tyrosine
However, this first effort to induce catalytic polyclonal antibodies failed, presumably due to the
inappropriate design of the hapten (transition-state analog) and/or the lack of proper technology for
7
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screening the individual antibodies for the catalytic ability. The first breakthrough in this field was
reported in 1986 independently by the two groups led by Lerner and Schultz. 3 The rational design
of transition-state analogs combined with the technical ability to generate cell lines producing
monoclonal antibodies via hybridoma technology,4 successfully generated a catalytic function in
antibodies. Indeed, monoclonal antibodies induced to a phosphonate transition state analog
displayed enzymatic characteristics which followed Michaelis-Menten kinetics for the hydrolysis of
an ester substrate.
This new class of enzyme-like catalysts has two significant benefits. First, since the
chemical complexity of enzyme functions makes the de novo design of an enzyme with the desired
properties extremely difficult, this novel approach of generating catalytic ability at the antibody
binding site may provide a powerful alternative to obtain tailor-made catalysts. Second, since the
antibody diversity is known to be greater than 108, it will be possible to synthesize enzyme-like
catalysts for various chemical reactions which have not yet been observed in nature.
Since the first reports of antibody catalysis in 1986, a large number of catalytic antibodies
have been prepared using haptens which are analogous to the putative transition states of chosen
reactions in terms of charge distribution and geometry. 5 Ester hydrolysis catalyzed by antibodies
raised against negatively charged, tetrahedral phosphonate haptens represents an initial success in
this area.6-9 Unfortunately, the rate accelerations achieved by catalytic antibodies are in most cases
several orders of magnitude lower than those attained by their natural enzyme counterparts. 7
Furthermore, efforts to prepare amidase-like antibodies, an obvious and important goal, have thus
far met with little success, owing largely to the greater strength of the amide bond.6 a
Aspartic proteases are a well-defined class of hydrolytic enzymes and an examination of
their reaction mechanism promised to serve as a good guide for hapten design and subsequent
preparation of amidase-like antibodies.10 The aspartic proteases carry two essential aspartate
residues, one in the neutral form and the other in the ionized form (Scheme 2). These residues are
thought to catalyze amide hydrolysis through at least three distinctive steps: (Step 1) The first
(ionized) aspartate accepts a proton from a water molecule to form hydroxide ion for subsequent
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attack at the amide carbonyl group; (Step 2) the second (neutral) aspartate residue stabilizes the
resulting tetrahedral oxyanion (the supposed transition state); and (Step 3) the proton accepted in
Scheme 2
Apo" Asp YO Asp * , 0O
0H
2R = 2 > R1 '2R.AoH2R' N ° 2R1 NH - H N R1
0GF-.H GHOf H' oH o H H
Asp,. A O Asp o Asp g
the first step is used to neutralize the leaving RNH- group. In the catalysis of amide hydrolysis,
the protonation of the leaving group in the third step is particularly important to drive the departure
of the amine, because the pKa's of neutral amines are significantly higher than those of alcohols. It
is commonly known that the negatively charged phosphonate analog mentioned above serves to
generate the essential acidic residue (Step 2) in catalytic antibodies. However the problems
associated with steps 1 and 3 had received little attention at the time our investigation was initiated.
In an effort to design more enzyme-like catalytic antibodies, we decided to design a zwitterionic
hapten incorporating both negatively and positively charged groups to induce both acidic and basic
catalytic groups in the antibody combining site. Unfortunately, the design and synthesis of such
bi-functional haptens are difficult and often very complicated. As an alternative strategy, we have
proposed simultaneously immunizing an animal with two structurally related but functionally
different haptens, each containing either a positive or a negative charge incorporated in an
appropriate transition-state analog.
When an animal is first immunized with one antigen and subsequently exposed to the same
antigen (homologous immunization), the host rapidly responds and produces a large number of
antibodies (mainly immunoglobulin G, IgG).ll If, on the other hand, the secondary immunization
is carried out with a different but structurally related antigen (heterologous immunization), the host
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also responds to this secondary antigen and produces IgG antibodies. These antibodies often have
higher affinity for the original primary antigen (a phenomenon referred to as "original antigenic
sin"). However, heterologous immunization also results in antibodies which bind to the secondary
antigen, or to both antigens. This cross-responding property of the host is believed to result from
the preferential stimulation of a subset of memory B cell clones that express the somatically
mutated variable region antibody genes. During the course of our efforts to produce catalytic acyl
transfer antibodies, we have realized that heterologous immunization with two haptens may
provide an elegant and simple method which can result in the introduction of more than one
catalytic amino acid residues into an antibody combining site. The immunization with hapten can
be also viewed as a method for generating a pool of antibodies in the array of the binding ability to
the hapten, and the catalytically active antibodies are then selected from the pool. Therefore, it can
be anticipated that heterologous immunization will lead to expansion of the pool in the two-
dimensional array of the binding abilities of antibodies to the two haptens prior to screening, which
should in principle increase the chances of finding an antibody with catalytic properties.
Thus, heterologous immunization protocol offers two distinct advantages over previous
approaches: (i) a means to introduce bi-functional catalytic residues into antibody combining sites
without recourse to a complex hapten synthesis and (ii) the ability to screen an expanded repertoire
of antibody combining sites for catalysts. Accordingly, we have designed two structurally related
haptens H5 (Hapten 5) and H2 (Hapten 2) with the goal of generating antibody catalysts to
hydrolyze ester SE and amide SA (see Chapter 3).
In the following chapter (Chapter 2), literature survey of catalytic antibodies with
hydrolytic activity and original antigenic sin concerning heterologous immunization are described.
In Chapter 3, the first effort utilizing a heterologous immunization strategy for the generation of
catalytic antibodies with hydrolytic activity is presented. In Chapter 4, studies of esterolytic
antibodies induced to haptens with a 1,2-amino alcohol functionality via homologous immunization
are also described.
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Chapter 2
Background
2.1. Antibody Catalysis
Since 1986, extensive efforts have been devoted to developing antibody catalysts utilizing a
transition state analog hapten. The results have been well summarized in a number of review
articles. 5 This section focuses solely on the strategies that have been used to generate catalytic
antibodies with acyl transfer capability.
2.1.1. Studies of Hydrolytic Monoclonal Antibodies Induced to Phosphonate
Transition State Analogs.
Tramontano 3 a observed that the immunoglobulin G (IgG), 6D4, raised by phosphonate
hapten la containing a picolinyl group, catalyzed the hydrolysis of ester 2a. The analysis of the
pseudo first-order rate showed enzyme-like saturation behavior (Michaelis constant, Km = 1.9
gtM, with a first-order rate constant, kcat = 2.7 x 10-2 sec-1), and this catalytic activity was
competitively inhibited in the presence of hapten lb (inhibition constant, Ki = 0.16 pM). These
observations suggested that the hydrolysis of 2a was occurring in the antibody binding site.
Interestingly, no antibodies elicited by the simpler phosphonate 3a showed any catalytic activity in
the hydrolysis of 2a. Though the role of the picolinyl appendage was not fully understood, the
catalytic activity of antibody 6D4 did not appear to be dependent on the presence of metal ion. In a
later report by Tramontano in 1988, however, antibodies elicited by phophonate 3a could
efficiently catalyze the hydrolysis of ester 2a.14 a In contrast to the previous antibody 6D4, whose
affinity to the substrate is similar to its hapten lb, the newly characterized antibody 57D8 had a
relatively weak substrate binding (cf. Km = 1.5 mM) and a five orders of magnitude difference in
binding to hapten 3 (cf. Ki = 0.05 gM). This difference was reflected on the rate enhancement
observed (kcat = 20 sec-1 , kcat/kuncat = 6.25 x 106) for antibody 57D8,14 a which was far superior
to that observed for 6D4 (kcatlkuncat = 960). In addition, pH-dependent rate profiles of both
antibodies 6D4 and 57D8 revealed that an amino acid residue with a pKa of about 9 might
11
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participate in their catalysis, and chemical modification experiments suggested that a histidyl or a
tyrosyl residue might be involved in the catalytic activity observed. The actual turnover rates of
these catalysts were not clearly reported in these papers, but the enzyme-like catalysis by the
antibodies was remarkable. (Although significant catalytic activity of antibody 57D8 was reported,
the value of kcat = 20 sec-1 stated in the reference 3a conflicted with the value to be secured from
the Lineweaver-Burk plot illustrated in the paper. If the conditions presented in the Experimental
were applied to the plot, the kcat should be 0.28 s -1, providing that the rate enhancement for the
57D8-catalyzed hydrolysis of 2a is 9 x 104, instead of 6 x 106 originally claimed in the paper
based on the kcat = 20 sec-1. Likewise, the rate enhancement of the alternate substrate 2b, which
should structurally resemble the hapten more closely than 2a, was originally reported to be 1.2
x10 5 by 57D8; but it also seems to be smaller than that, perhaps -103, if the above conditions were
applied.)
Schultz et al. reported that the immunoglobulin A (IgA) MOPC167, which represents a
well-characterized class of antibodies specific for phosphorylcholine 4a, catalyzed the hydrolysis
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of p-nitrophenyl N-trimethylammonioethyl carbonate 5a.3 b MOPC167 catalysis displayed
saturation kinetics with kcat = 0.4 min- 1 and Km = 208 ,gM at pH 7.0, and it was also strongly
inhibited by 4b with Ki = 5 gM. The authors speculated that the phosphate group in 4a might
behave as a mimic for the transition-state of the hydrolysis of 5a, and this particular antibody could
stabilize this transition-state.
0
R- 0 0 O-R ,C3'°OH
4a =50 2N 0 2N
4a R = H R = H5a R = (CH2)2NMe 34b R = p-nitrophenyl 5b R = CH3
Subsequently, this speculation was proven by the fact that the use of phosphonate 5c successfully
induced catalytic antibodies (IgG) hydrolyzing 5b (kcat = 0.5 min- 1 and Km = 630 gM at pH
7.9).14b It was also demonstrated that a tyrosyl residue plays an important catalytic role based on
the chemical modification of MOPC167. Indeed, the x-ray structure of the Fab'-4a complex of
one antibody, McPC603, indicated specific interactions between Tyr3 3 H, Arg52 H of the heavy
chain and the phosphate group of the hapten. Based on this structural information, Schultz
undertook site-directed mutagenesis of Tyr33H and Arg52H in MOPC167.15 Mutation of Tyr33H to
Phe (Y33F), Glu (Y33E), and Asp (Y33D) had little effect on the catalytic activity (kcat), while
mutation to His (T33H) increased the kcat from 0.71 to 5.71 min -1. In contrast, mutation of
ArgS2H to Glu (R52Q) and Cys (R52C) considerably lowered the kcat (greater than 20-fold,
resulting in no detectable catalysis), presumably due to the loss of the positive charge necessary for
stabilization of the negatively charged oxyanion in the transition-state of the reaction. These results
not only demonstrate the importance of electrostatic interactions in catalysis of the antibody, but
also show that introduction of appropriate amino acid residues in the combining site can enhance
the catalytic activity.
Monoclonal antibodies were generated by tripeptide phosphonate 6 aiming to hydrolyze
ester 7a and amide 7b.1 6 Eighteen out of 25 monoclonal antibodies were found to accelerate the
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hydrolysis of ester 7a, while no antibodies showed ability to hydrolyze amide 7b. Even though
the immunized hapten 6 was racemic, five of the characterized catalytic antibodies had a definite
preference (greater than 90%) for the D-phenylalanyl isomer over the L-isomer. However, since
6H
0
--Y
7aX =O
7b X = NH
the observed rate enhancements were modest (only 30-270 fold rate accelerations at pH 8.0 were
observed), these stereospecificities must have been calculated by the initial rate assuming that the
racemic product formation due to the spontaneous hydrolysis is not competing with the antibody-
catalyzed reaction, rather than actually measuring the enantioselectivity. Furthermore, small
differences between Km and Ki (all of the reported Km/Ki of antibodies were less than 10)
indicate poor turnover. These results suggest that the phosphonate moiety in 6 probably
contributes insignificantly, compared to the functionalized tripeptide moiety, to the overall binding
energy of the hapten to antibody.
In 1989, two remarkable papers were published by Lerner's group. In the first, the
stereospecific hydrolysis of esters 8 bearing either R or S enantiomeric alcohol 9 was achieved by
two separate classes of catalytic antibodies raised by the racemic phosphonate transition state
analog 10.8b In their study, 11 out of 18 antibodies were identified as catalysts for the hydrolysis
of ester 8. Among them, nine were enantiospecific for the hydrolysis of ester (R)-8, whereas the
other two were stereospecific for hydrolysis of the antipodal ester (S)-8. Two antibodies, 2H6
14
and 21H3, were further characterized by Michaelis-Menten kinetics. Remarkable rate acceleration
was observed in the hydrolysis of (R)-8 with antibody 2H6, giving kcat/kun = 8 x 104. In contrast
to its weak binding to (R)-8 (Km = 4 mM), strong binding to the parent acid 11 (which
0 O O0 O
H H
(R)- or (S)-8 10
cOH lOyOH -NJoH
H
(R)-9 (S)-9 11
competitively inhibited the hydrolysis of (R)-8 with Ki = 50 gM) was noted. This result
suggested that amino acid residue(s) complementary to the negatively charged acid exist in the
antibody combining site; indeed phosphonate 10 also strongly inhibited the catalytic activity of
2H6 with Ki = 2.0 gM. On the other hand, 21H3 was specific for the hydrolysis of the antipode
(S)-8 with modest rate acceleration (kcatlkun = 1.6 x 103). Product inhibition was not detected (Ki
> 0.2 mM) with either (S)-9 or 11. Competitive inhibition by hapten 10 was observed with Ki =
0.19 pM. The enantioselectivity of both antibodies was estimated at greater than 98%, although,
as before, these numbers were derived by using the assumption noted above.16
The second report concerned the hydrolysis of the activated-amide bond of 12a with an
antibody elicited by phosphonamidate 13a.6a The catalytic antibody NPN43C9 was obtained from
a pool of 44 antibodies binding to the hapten 13a, and the rate acceleration for hydrolysis of p-
nitroanilide 12a was remarkably high (kcat = 0.05 min- 1, kcatlkun = 2.5 x 105). The antibody
binds tightly to both substrate 12a and hapten 13b (Km = 562 pM and Ki = 10 RM) compared to
the previous 2H6. However, since this catalytic antibody also binds tightly to the products (the
dissociation constants of p-nitroaniline and the product acid 11 were 9 M and 28 M,
respectively), the turnover of this catalysis is probably limited. No otherp-nitroanilide derivatives
were accepted as a substrate, suggesting that NPN43C9 is highly specific to substrate 12a.
15
Indeed, even m-nitroanilide 12b did not serve as a substrate but as a competitive inhibitor for
hydrolysis of 12a, giving Ki = 804 pM. Further mechanistic aspects of this unique catalyst will
be discussed in 2.1.2.
H H
Scl N O HIC~cN~OH 0 2NO N R0 2N H H
12a p-nitro 13a R = (CH2 )3COOH
12b m-nitro 13b R = CF3
H
14a R = NO2
14b R = C1
14c R = CHO
14d R =H
More recently, Janda et al. reported the generation of catalytic antibodies raised to
phosphonamidate 13a by means of a combinatorial libraries procedure. 6 b This technology is
expected to be an alternative to the hybridoma technology generally used in this field. It results in
an Fab fragment of an IgG molecule instead of a whole IgG (additional advantages of this
approach are discussed in the references' 7). The generated Fab-antibodies binding to 13a catalyze
the hydrolysis of ester 14a but not of amide 12a, unlike the previous reported antibody
NPN43C9. One antibody, Fab 1D, hydrolyzed ester 14a with Michaelis-Menten parameters, kcat
= 0.25 min-1 and Km = 115 gM, and the observed rate acceleration was -103.
In summary, phosphonate transition-state analogs have successfully generated a number of
esterolytic antibodies with rate accelerations in the range of 102-104. However, the amidase-like
activity of antibodies has been observed in only one case, which utilized an activated amide as a
substrate. The ability to generate catalytic antibodies capable of cleaving an amide bond with high
catalytic efficiency still remains a major challenge in this field.
2.1.2. Mechanistic Studies of Catalytic Monoclonal Antibodies Induced to
Phosphonate Transition State Analogs.
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Since most catalytic antibodies with acyl transfer activity are far less efficient than naturally
occurring hydrolytic enzymes such as proteases, it is important to understand the differences in the
mechanistic course between the two proteins. As described in 2.1.1., some kinetic studies of
hydrolytic antibodies obtained to date have been reported; however, only a few detailed
mechanistic studies have been undertaken. In this section, two mechanistic studies of catalytic
antibodies raised to phosphonate transition state analogs are summarized.
Benkovic et al. reported detailed kinetic investigations of the hydrolysis of ester 14a and
amide 12a catalyzed by antibody NPN43C9 (discussed in 2.1.1.).7a Steady-state and pre-steady-
state kinetic experiments indicated that the pH-rate profiles for both substrate 14a and 12a
exhibited an apparent pKa of 9.0 (the kcat became independent above pH 9, while Km was
independent over the entire pH range examined, pH 7-10). This appeared to be consistent with the
presence of a catalytic group with pKa of -9 in the antibody combining site (presumably acting as a
general base). However, solvent isotope effect studies on the hydrolysis of amide 12a were not
consistent with this interpretation. The pKa in D 20 shifts to -10 (a much larger change than is
seen with normal acids), suggesting that the observed pKa is due to a change in the rate
determining step, and there is no measurable solvent isotope effect on kcat in the pH independent
region. Furthermore, kcat for ester 14a at pH >9 is limited by the release of p-nitrophenol (PNP),
suggesting that the pKa in the ester kcat-pH profile is also due to a change in rate limiting step.
Neither the rate constant for release of p-nitrophenol nor the thermodynamic binding constant for
association of the anilide substrate were pH sensitive over the observed pH range. As a result of
these findings, a kinetic scheme was proposed for this particular antibody which involves the rapid
formation of a reactive acyl-antibody intermediate, followed by its hydroxide-mediated hydrolysis
to afford the product acid and phenol or aniline. This acyl-antibody intermediate formation was
also supported by the lack of 180 exchange in the antibody-catalyzed hydrolysis of 12a. In
addition to these studies, they have recently investigated the substituent effects on the antibody-
catalyzed hydrolysis of phenyl esters 14a-d.7b Thus, the correlation of or values for the para
substituents with the rate of antibody-catalyzed hydrolysis (Hammett correlation), was expected to
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provide information about the nature of the rate limiting step, including the phenol product release.
Thus, the observed p value of 2.3 in the NPN43C9 catalyzed hydrolysis of various para-
substituted phenol ester substrates was significantly larger than the values expected for a general
base catalyzed reaction (which would give p 1), again supporting the acyl-antibody intermediate.
They also proposed that the antibody nucleophile acylated by the substrate might be the imidazole
group of a histidine residue, although there is little enzymatic precedent for nucleophilic attack by
this residue. Furthermore, the lack of a solvent isotope effect on acylation and the high p value
observed both indicated that protonation of the leaving group either does not occur or lags behind
bond cleavage. This is in sharp contrast to the hydrolysis of anilides by chymotrypsin, where a
protonated imidazole group of a histidine residue simultaneously protonates the anilide leaving
group to result in the cleavage of amide bond.
To support the hypothesis that an acyl-imidazole was a key catalytic intermediate, Benkovic
recently used site-directed mutagenesis to probe the role of the catalytic residues of NPN43C9. 7C
The computer model simulation of the Fv fragment suggested that two amino acid residues, His
L91 and Arg L96, might play important roles to catalyze the hydrolysis. Thus, two mutants, H-
L91-Q and R-L96-Q, were made and their properties compared with those of original antibody.
The catalytic activities of both mutants for hydrolysis of 14b were below the detection limits: the
activity was at least 20-fold lower than that of the wild type. Moreover, studies of the
thermodynamic dissociation constants (Kd) of these antibodies for the hapten 13b and the products
of ester hydrolysis (PNP and the product acid 11) demonstrated that the Kds of the mutant H-L91-
Q were virtually the same as those of the wild type, while the Kds of the mutant R-L96-Q were 2-
10 times higher than those of the wild type. These results indicated that His L91, which
presumably attacks the carbonyl group of the ester to form the acyl-imidazole intermediate, plays a
significant role for hydrolysis, while Arg L96 stabilizes the forming oxyanion.
In collaboration with Schultz, Martin et al. reported mechanistic studies of a tyrosine-
dependent catalytic antibody.9 Antibody 20G9, elicited by phosphonate transition-state analog 15,
catalyzed the hydrolysis of ester 16, which was characterized by a multiple-turnover pre-steady-
18
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state burst. The burst was caused by partial product inhibition by phenol (Ki = 2.5 gM), which
lowered both kcat (from 4.9 min-1 to 0.54 min-1) and Km (from 300 ,gM to 36 gM) by almost an
order of magnitude without affecting kcad/Km. The acid limb of the steady-state kcat pH profile of
the antibody had a pKa of 9.6, suggesting a catalytic role for tyrosine. Furthermore, the kinetic
details of the burst, along with the observation that an essential tyrosine on the antibody is acylated
by substrate analog 17 (which, it was hoped, should afford a relatively stable acyl-intermediate),
provided insight into the mechanism of the hydrolysis of 16. The data suggested an inhibition
mechanism in which phenol binds to a covalent O-acetyltyrosyl intermediate, showing hydrolytic
deacylation. Although the data was not entirely consistent with this mechanism, it allowed the
proposal of two possible inhibition mechanisms; in one, phenol was a mixed partial inhibitor of
phenyl acetate hydrolysis, and in the other, phenol caused a nonproductive binding with the
substrate. Since these proposed tyrosine-dependent mechanisms were not quite consistent with the
results of the site-directed mutagenesis study discussed in 2.1.1., further study is required to draw
a mechanistic conclusion.
When these mechanistic aspects were compared with highly-evolved proteases such as
chymotrypsin, the antibodies lack some important features found in the proteases. First, the
antibodies do not appear to utilize general acid catalysis; the leaving group departs essentially with
a full negative charge. Second, attack by the nucleophile, in these case a histidine and a tyrosine
rather than a serine, likewise is not abetted by general base catalysis. Third, product inhibition
reduces the catalytic efficiency, and in the cases of the p-nitrophenyl ester hydrolysis product,
desorption represents the rate-limiting step. These catalytic residues in the antibodies were
presumably generated by charge-complementarity between hapten and antibody. The negative
charge of the phosphonate transition-state analog presumably induces a positively charged residue
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(e.g. the arginine and the protonated histidine in NPN43C9), or to some extent induces a residue
as a proton donor (e.g. the tyrosine in 20G9). However, one of the observed catalytic residues is
likely to behave as a nucleophile rather than an acidic residue to stabilize the developing oxyanionic
transition-state intermediate. This unexpected property also brings the pH-optimum of the catalytic
activity in the basic pH range (>9) owing to the ionization of the residue. In order to generate
better catalytic antibodies, it is important to (1) increase our understanding of hapten-antibody
charge complementarity, and (2) design haptens to induce the multiple (acidic and basic) catalytic
residues, which would enhance not only catalytic activity but also keep the pH-optimum of the
activity near neutral pH.
2.1.3. Transesterification Catalyzed by Monoclonal Antibodies Induced to
Phosphonate Transition State Analogs.
Since transesterification is one type of acyl transfer reaction, its transition-state is
essentially the same as that of hydrolysis. Therefore, the use of phosphonate transition-state
analogs could generate catalytic antibodies with transesterification activity. However,
transesterification in water is less favorable than hydrolysis because water is present in vast excess
and is preferred as a reactant. To avoid undesired hydrolysis, a high specificity of the antibody for
the transition-state of the reacting ester and alcohol is required.
In order to eliminate this complexity, Benkovic et al. first examined intramolecular
lactonization. 18a Antibody 24B 1, generated by a cyclic phosphonate ester transition-state analog
18, catalyzed the intramolecular cyclization of 19a. This particular antibody had a high specificity
to substrate 19a (Km = 76 gM). For example, neither cumarine ester 19b nor phenyl 5-
hydroxypentanoate (which lacks the acetoamide methyl portion) are substrates. The reaction of
24B 11 with 19a was competitively inhibited by the addition of 18, with Ki = 0.25 ,uM. Although
the rate enhancement (kcat/kun = 167, kcat = 0.5 min-1) was modest, the cyclization was observed
to be highly stereospecific, affording the lactone with 66% ee (which is calculated to be 94% ee if
the product formation in the competing uncatalyzed cyclization is ignored). Subsequently, the
authors reported a bimolecular aminolysis reaction catalyzed by the same antibody 24B 11.18b The
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lactone 20 was stereospecifically (>90% ee) opened by 1,4-phenylenediamine affording amide
19c in the presence of 24Bll. These results indicated that antibody catalysis for trans-
esterification could be realized by the use of a phosphonate transition-state analog.
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Janda et al. reported that antibody 21H3 raised by transition-state analog 10 catalyzed the
bimolecular trans-esterification between the activated vinyl ester 21 and a variety of aromatic
alcohols.8c This catalytic antibody had shown modest hydrolytic activity to (S)-8 (kcat/kun = 1.6 x
103) and high specificity to the ester (S)-8 compared with the alcohol (S)-9 and the acid 11 (see
2.1.1.),8b and indeed the trans-esterification of 21 to (S)-8 could be stereospecifically promoted
without the significant hydrolysis side-reaction. It was postulated that the reaction proceeded
through a covalent intermediate (ping-pong mechanism), which was also proposed for the reaction
with the catalytic antibodies NPN43C9 and 20G9. In addition, the flexibility of this reaction to a
variety of aromatic alcohols also suggested that this catalyst has an induced fit property. Although
nothing in the design of the hapten dictated either covalent catalysis or induced fit, these
encountered properties might be due to a consequence of immunological diversity.
Schultz et al. recently reported that the aminoacylation reaction was catalyzed by antibodies
elicited by phosphonate diester transition state analog 22.19 Racemic hapten 22 induced 39
monoclonal antibodies, and among them four antibodies preferentially accelerated the reaction of L-
alanine ester 23. Of the four, three were D-selective, and one demonstrated no selectivity.
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Antibody 18R.136.1 was further characterized and showed a significant rate acceleration for
aminoacylation of the 3'-hydroxy group of thymidine 24 with L-alanine ester 23 with an apparent
second-order rate constant (kcat/Km = 5.4 x 104 M-lmin-1). This remarkably efficient catalysis by
the antibody (compared with the uncatalyzed reaction, 2.6 x 10-4 M-lmin-l) selectively promoted
the aminoacyl transfer reaction in water without the hydrolytic side-reaction. The antibody exhibits
sequential binding, with Michaelis constants of 770 gM and 260 !lM for acyl acceptor 23 and
donor 24, respectively, and a dissociation constant of 240 pM for hapten 22. With this
extraordinarily strong affinity of the antibody to the transition state analog, efficient and selective
transesterification was attainable.
2.1.4. Other Approaches to Generating Catalytic Antibodies with Acyl Transfer
Capabilities.
In 1989, Schultz introduced a new strategy to generate catalytic antibodies: electrostatic
interactions between a hapten and the complementary antibody were utilized to generate catalytic
amino acid side-chains (catalytic residues) in an antibody combining site.20 The use of hapten 25,
which contains a positively charged ammonium ion, generated antibodies which effected 13-
elimination of 26 with typical enzyme-like saturation kinetics. Chemical modification studies and
the pH dependence of kcat suggested that a carboxylate group plays an important role in this
reaction. Furthermore, the probability of the finding catalytic active antibodies among the isolated
monoclonal antibodies was 66%, indicating that this strategy is useful in designing haptens.
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Subsequently, Janda et al. generated esterolytic antibodies by utilizing haptens based on the
above idea that catalytic residues can be induced in an antibody active site via charge
complementarity. 2la The authors examined monoclonal antibodies generated against pyridinium
salt hapten 27 and non-charged pyridine hapten 28. Immunization of haptens 27 and 28
produced 23 and 21 monoclonal antibodies, respectively, and their esterolytic activities to 29 were
studied. Seven out of 23 antibodies induced to hapten 27 were found to be catalytic while none of
the antibodies to 28 showed a tendency to accelerate the rate of hydrolysis of ester 29. Antibody
30C6, which exhibit the highest catalytic activity, hydrolyzed 29 with kcat and Km of 5 x 10-3 min-
1 and 1.1 mM, respectively, providing kcat/kun = -103. (Although they claimed that this catalysis
showed 107 -fold rate acceleration compared with ko = 6 x 10-10 min-1 where ko is the water-
catalyzed hydrolysis of 29, we believe that the proper rate enhancement should be obtained by the
comparison of the kcat with the zero-buffer-catalyzed rate constant kun. While Janda reported
N10 -8 min-1 for the kun, it turned out to be 6 x 10-6 min-1 by our independent kinetic-analysis. A
subsequent report by Janda 21c was actually consistent with our analysis.) The pH-rate profile of
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antibody 30C6 revealed that a basic residue, whose pKa was determined to be 6.3, plays a role of
the catalysis (the kcat became pH-independent above pH 7). Janda et al. later reported that
antibodies elicited by benzoic acid hapten 30 also catalyzed the hydrolysis of ester 28, while none
of the antibodies raised by non-charged hapten 31 catalyzed the hydrolysis.21b In contrast to
30C6, the antibody 27A6 raised by 30 showed a pH dependence for the entire pH range 7-10,
with the kcat increasing with pH. Furthermore, no antibodies generated by the quaternarized
ammonium salt hapten 32 catalyzed the hydrolysis. These studies suggested that the combination
of either a cationic or an anionic charge (a pyridinium salt or a benzoate group) and a neutral
representation of the transition-state (a hydroxy group) was required to induce hydrolytic activities
in antibodies. Unfortunately, the hapten design is strictly limited to this particular substrate due to
the incorporation of the point charge into an adjacent ring system.
33 + Zn2 +
0K KS33Zn2+
N R IgG +33Zn 2+ IgG.33Zn2+
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Most recently, Janda et al. reported that one of the antibodies previously generated by
hapten 27, 84A3, catalyzed the hydrolysis of picolinate ester 33 in the presence of Zn2 + metal
ion,2ld although no other antibodies including antibody 30C6,2 lb exhibited catalytic activity in the
presence of Zn2+ . Interestingly, antibody 84A3 did not exhibit the hydrolytic activity in the
absence of Zn2+ or in the presence of other metals (Cd2+, Co2+, Ni2+). It has been postulated that
(1) the positive charge of hapten 27 generates carboxylate residues which may act as ligands for
the incoming metal, and (2) the methyl moiety on the pyridinium salt provides some spatial latitude
to accommodate a metal ion in the antibody binding pocket. The initial rate of the antibody-
catalyzed hydrolysis of 33 in the presence of Zn2 + was kcat = 2.7 min-1 , while the uncatalyzed
24
background rate and the metal-catalyzed background rate were determined to be kun = 2.1 x 10-4
min- 1 and kun .Zn 2+ = 2.2 x 10-3 min-1, respectively. However, the affinity of 84A3 to both Zn2 +
(Ko = 36 pM) and 33oZn2 + (K33.Zn2 + = 840 jiM) were found to be much weaker than to 33 (K33
= 3.5 gM), indicating that strong non-productive inhibition by 33 should occur during the
hydrolysis, which would limit the turnover of this reaction.
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Prior to Janda's report, Iverson and Lerner demonstrated that incorporation of a metal
cofactor into the antibody binding site successfully produced proteolytic activity.2 2 Antibodies
were generated by hapten 34 using an inert octahedral Co(III) trien-complex with a peptide (but
not the transition-state analog), and the antibody thus generated (28F11) catalyzed the hydrolysis
of amide 35 in the presence of the trien and metal ions. A variety of metals could be used, but
efficient catalysis was seen only for those capable of adapting an octahedral geometry with trien
ligands, such as Zn2+, Ga3+, In3+, etc. Although the exact kinetics were not investigated, kcat = 6
x 10-4 sec- 1 and 400 turnovers per antibody binding site in the presence of Zn2+°trien were
claimed. (Although remarkable catalysis by antibody 28F11 was observed, several experiments
should have been carried out in order to evaluate this catalysis: for example, the negative controls
including the background hydrolysis rate by Zn2+°trien complex, the inhibition constant of hapten
34, and dissociation constants of Zn2 +, Zn2+-trien and the peptide substrate for the antibody.)
The metal cofactor-antibody catalysis may be improved by (1) design of the metal complex
incorporated in a transition state analog, and (2) incorporation of a basic residue in the antibody to
promote the deprotonation of the water molecule which coordinates to the metal cofactor.
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Generation of catalytic residues based on the concept of charge complementarity and the
incorporation of a metal cofactor near or into the antibody combining site will be powerful tools to
generate catalytic antibodies with high efficiency. However, the lack of a general approach to
design the hapten which incorporates the charge(s) and/or the metal cofactor has hindered its
application to a wide variety of substrates. There is a strong demand to achieve a more general
design of haptens which are potentially applicable to any acyl transfer reaction.
2.1.5. Applications of Hydrolytic Monoclonal Antibodies.
Since monoclonal antibody generally exhibits high affinity to the molecule used for
immunization, it is expected that antibody has a remarkable sensitivity to the molecular structure.
This property accounts for the stereospecificity of catalytic antibodies for either the R or S stereo
isomer of a chiral substrate, resulting in kinetic resolution. Janda et al. reported that a lipase-like
antibody generated by racemic phosphonate hapten 36 catalyzed the hydrolysis of meso-37 to
yield one enantiomer predominantly. 2 3 Antibody 37E8, selected from 33 monoclonal antibodies,
hydrolyzed meso-37 with kcat = 0.007 min-1, Km = 177 gM, and Ki = 7.0 p.M to afford (1R,
4S)-38 with 86% ee. Although the inherent enantioselectivity of 37E8 were excellent (>98% ee),
its poor rate acceleration of the hydrolysis significantly lowered the actual optical purity of the
product of 38.
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Eliciting the therapeutic potential of catalytic antibodies is one of the most exciting
challenges in this field. The first application was recently reported by Landry et al.: the antibody-
catalyzed degradation of cocaine (40 to 41).24 Antibodies were generated by a phosphonate
transition-state analog 39, and two out of 29 monoclonal antibodies catalyzed the hydrolysis of
cocaine 40. One of them, 3B9, followed Michaelis-Menten kinetics with kcat = 0.11 min -1, Km =
490 [tM, and Ki < 2M. This antibody hydrolyzed 40 with 540-fold rate enhancement compared
with the spontaneous rate ko = 2 x 10-4 min-1. However, it was suggested that, in order to
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deactivate cocaine before significant partitioning into the central nervous system (CNS) (i.e. the
activity required for therapeutic utility), a catalytic antibody against cocaine should ideally have a
turnover number kcat >2 s-1 (120 min-1) and a Km < 30 M. Nevertheless, this result
demonstrates the potential for development of catalytic antibodies for therapeutic use.
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2.1.6. Antibody-Catalyzed Rearrangement of the Peptide Bond
The deamidation of Asn residues has been implicated in protein denaturation of proteolytic
processes leading to protein degradation in vivo, and the loss of enzymatic activity. Benkovic et
al. envisioned that properly selected antibodies might restrain the Asn side-chain amide carbonyl
and n+l amide nitrogen of the peptide backbone 42 in an alignment and distance favorable for
reaction to form succinimde intermediate 43.25 That in turn would hydrolyze to Asp deamidation
product 44 and the isoaspartyl (IsoAsp) P-shift mechanism product 45. In order to achieve this
two-step reaction sequence, the structure of the hapten should resemble three independent
succinimde-like tetrahedral transition-states (T-1, T-2, and T-3). Based on this consideration
hapten 46 was designed and synthesized, and monoclonal antibodies were raised against this
hapten. Two antibodies, 2E4 and 24C3, out of 30 antibodies were identified as catalysts for the
rearrangement. The further characterized antibody 2E4 showed an enzymatic activity with
Michaelis-Menten parameters, kcat = 1.2 x 10-4 s- 1 (7.2 x 10-3 min-1), Km = 193 RM, Ki < 0.1
jgM. The rate acceleration of this catalysis was 70-fold based on ko = 1.7 x 10-6 s- l. Furthermore,
four other antibodies were found to catalyze only the hydrolysis of succinimide 43 with significant
stereospecificity. One of them, 24C3, is not a catalyst for the formation of 43, but a catalyst for
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the hydrolysis of 43 yielding products 44 (Asp) and 45 (Iso) with a pronounced Iso/Asp ratio of
16 for the L-isomer, but a decreased Iso/Asp ratio of 1 for the D-isomer. On the other hand, the
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rearrangement catalysts 2E4 and 43C3 hydrolyzed 43 with an Iso/Asp ratio of -2 for L-isomer and
an Iso/Asp ratio of ~5 for the D-isomer. This result implies that antibody 24C3 preferentially
stabilized the transition-state T-3 over T-2 in L-isomer 43 affording IsoAsp 45. However, the
structure of hapten 46, providing the negatively charged phosphonate group in the T-2 site and the
uncharged hydroxy group in the T-3 site, presumably would generate antibodies with the property
of preferentially stabilizing transition state T-2 rather than T-3. This conflict between the
properties of the isolated antibodies and the rationale of the hapten structure is puzzling.
Nonetheless, the significant features of these catalytic antibodies suggest that (1) an intramolecular
nucleophilic cyclization provides a significant advantage for promoting the energetically hindered
reaction such as deamination, and (2) the antibody-catalyzed rearrangement of Asp-Gly to IsoAsp-
Gly can be a potential strategy for deactivation of protein function.
2.1.7. Studies of Polyclonal Antibodies with Hydrolytic Activity.
Compared with monoclonal antibodies which have been used most popularly in the
catalytic antibody research, polyclonal antibodies offer a rapid and cost-effective alternative.
However, the initial failure of Raso et al. to generate antibody catalysis discouraged the
exploitation of polyclonal antibody catalysis. Gallacher et al. recently described the generation of
polyclonal antibodies with hydrolytic activity. 2 6a
A sheep was immunized twice (in 29-weeks intervals) with phosphate transition state
analog 47a, and 2 weeks after the second injection polyclonal antibodies PCA 270-29 were
isolated from antiserum. The purified PCA 270-29 catalyzed the hydrolysis of carbonate 48,
which followed Michaelis-Menten kinetics. The Michaelis constant (Km) was determined to be 3.3
gM with at least 25 turnovers at pH 8.0. Although the exact first-order rate constant (kcat) could
not be determined because the concentration of catalytic antibodies in the polyclonal pool was
unknown, if the assumption was made that 10% of the total concentration of antibodies were
catalytic (which is probably reasonable), kcat would be determined to be 0.29 min-1 and thus
kcatkun = 1.5 x 103. The catalytic activity was competitively inhibited by the presence of 47b,
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providing Ki = 9 nM. It is noteworthy that neither sulfoxide hapten 49, sulfone hapten 50, nor
antiserum of non-immunized sheep gave catalytic polyclonal antibodies, indicating the importance
of immunization with a phosphate transition state analog.
It was subsequently reported that re-immunization of the same sheep with 47a (22-weeks
after the second immunization) produced catalytic polyclonal antibodies PCA 270-22 with amidase
activity.2 6b PCA 270-22 had a slightly higher hydrolytic activity for carbonate 48 than PCA 270-
29 with kcat = 1.4 s -1 (assuming 10% of the antibodies were catalytic), while Km = 4.0 gM was
virtually the same. Furthermore, PCA 270-22 also catalyzed the hydrolysis of amide 51 with Km
= 5.4 gM and kcat = 6.0 x 10-4 s-1 (the same assumption was made). They also claimed that this
catalytic activity was seen only at basic pH (>9) while at pH 8 the hydrolysis was immeasurably
slow.
The demonstration that it is possible to produce polyclonal catalytic antibodies with
Michaelis characteristics should facilitate the kinetic investigation of a wide range of catalytic
antibody systems. The simplicity of polyclonal antibody production should aid the screening of
immunogens for their ability to generate catalytic antibodies with particular kinetic characteristics.
However, the modest kcat of these antibodies still prevents the practical use of this technology in
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antibody catalysis. To improve the modest activity of polyclonal antibodies, it is required that not
only their catalytic efficiency in individual catalytic antibodies but also the probability of catalysts
among all of the isolated antibodies must be increased.
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2.2. Original Antigenic Sin
Antibodies are a highly diverse family of structurally distinctive proteins. Tremendous
research into the question of the genetic basis of antibody diversity has revealed that the antibody
variable (V) region diversity arises from four genetic sources, namely, diversity present in
germline multigene families, combinatorial diversity, junctional diversity, and somatic mutation.
This expansion of antibody repertoire is triggered by an immune response in which naive B-cells
are stimulated by an antigen. This immune response to an antigen depends not only on the nature
of the antigen (e.g. the structure) but also on the immunological history of the recipient. The trivial
case is that, when an animal which has been immunized with an antigen is again stimulated by the
same antigen, the secondary immune response rapidly occurs providing a large number of
antibodies with a greater affinity to the antigen than those in the primary immune response.
However, the situation is more complex when the secondary antigen is not identical but is
structurally similar to the primary antigen. In some cases, the produced antibodies have a higher
affinity to the primary (original) antigen than the secondary antigen, a phenomenon referred to as
"original antigenic sin". In the context of a heterologous immunization strategy for catalytic
antibody production, a literature survey of "original antigenic sin" is presented below.
2.2.1. Early Studies of "Original Antigenic Sin".
In 1953, Francis reported a phenomenon called "original antigenic sin" in studies of
various cross-reacting strains of influenza virus. 12a When immune animals are stimulated with a
vaccine (antigen) related to but not identical with the primary antigen, their response is made up of
antibodies that react better with the primary antigen than with the antigen that has triggered the
response (the secondary antigen). This overriding effect of the primary vaccine has been called
"original antigenic sin". The phenomenon is interpreted in terms of a hypothetical set of cells
capable of manufacturing cross-reacting antibodies and responding to stimulation by either of the
antigens. If the primary antigen is used for recall, the product of these cells is part of the standard
secondary response; if a cross-reacting antigen is used, the response is still a "recall", even though
only a partial recall. It is not a primary response.
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In 1966, Fazekas de St. Groth et al. hypothesized that the abolition of the primary response
should still allow manifestation of "original antigenic sin" as long as the capacity to respond is not
abolished. 2 7 Since appropriate X-irradiation is known to prevent a primary, but not a secondary,
response, it was thought that this phenomenon might help elucidate whether a given response is of
primary or secondary character. It was shown that whole-body X-irradiation, sufficient to abolish
primary but not secondary production of antibodies, left all manifestation of original antigenic sin
untouched, suggesting that the response towards the primary antigen is of a secondary type.
Furthermore, the injection of large amounts of the second antigen produced a complex response to
both antigens: a primary response towards the secondary antigen occurred at the same time as the
secondary response towards the primary antigen. These results might be interpreted in the
following way: The first injection stimulates the multiplication of cell clones carrying various
specificities, including clones producing only cross-reacting antibodies. After the second injection,
the antigen is preferentially trapped by these latter clones and stimulates their multiplication. In this
manner, a restricted population of antibody-producing cells should be observed under conditions
of "original antigenic sin", leading to more homogeneity with respect to affinity of the antibody
molecules produced.
In contrast to these reports, Levin et al.28 reported in 1972 that immunization of a-DNP-
poly-Lys followed by e-DNP-poly-Lys, or the reverse, provided cross-reactive antibodies to both
antigens, while the preference of antibodies to the secondary antigen over the primary antigen was
observed. This result suggested that when the antigenic determinants of the primary and the
secondary antigens are identical, the phenomenon of "original antigenic sin" may not necessarily
occur. Nevertheless, these three studies introduced the crossreactive property of immunity which
results in the "immune history" of an animal having a direct bearing on its "immune status" to
antigens that may be encountered in the future.
2.2.2. Studies of "Original Antigenic Sin" at the Cellular Level Using Haptens.
In 1971, Bussard et al. studied "original antigenic sin" at the cellular level using two cross
reacting haptens: m-aminobenzoic acid (mB) and m-sulfanilic acid (mS).29a This study provided
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three significant advantages over the previous reports. First, the number of antibody-forming cells
(AFC) was measured by the local hemolysis technique using red blood cells coupled to the
haptens. In this way, if the complement is present, the antibodies lyse the red cells and form a
plaque surrounding the white cells, which allows identification of specific antibody-forming cells.
Second, in the previous studies of cross-reactivity between multi-determinant antigens such as a
virus, apparent cross-reaction could be due to the identity of one or several antigenic determinants
on the virus coat. In contrast, the use of the structurally similar, simple haptens allows the
identification of true cross-reactivities, where the same antibody site binds the two haptens with a
different degree of affinity. Third, since neither antibodies generated by repeated immunization
with mB nor mS (homologous boost) cross-reacted with either of the un-immunized antigen, the
results were expected to clearly show occurrence of "original antigenic sin" when the animal was
immunized with two different antigens (heterologous boost). Their studies of homologous boost
(mB-mB and mS-mS) and heterologous boost (mS-mB and mB-mS) revealed that (1) in the
homologous booster injection, the response towards mS is generally stronger than that towards
mB, which can be explained either by differences between the immunogenicity of the two haptens
or by differences in the sensitivity of the detection of AFC against the two haptens, (2) in the case
of mS-mB injection some animals did not respond at all, which was not observed in the case of
mB-mS injection, and (3) in the case of mS-mB injection the responses towards mS were stronger
than those towards mB (a phenomenon of "original antigenic sin"), while in the case of mB-mS
injection the responses toward both haptens were of similar intensity. The responses to the
primary antigen occurred in both cases of heterologous boost, although strength of the appearance
of "original antigenic sin" might be reflected by the immunogenicity of antigens. Note that these
studies compared the frequencies of the cells responding to each antigen but did not compare the
specificity of the antibody produced by single cells.
In order to determine the specificity of the antibody produced by each cell, particularly to
score the cross-reacting antibody-forming cells, inhibition procedures in the presence of either
antigen to distinguish between mB-specific cells and mS-specific cells were subsequently
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applied.2 9b The studies revealed that (1) in the case of mS-mB injection, a large population of cells
exclusively showed anti-mS properties, and (2) in the case of mB-mS injection, a high proportion
of cells were exclusively specific to mB, although some cells were found to have great specificities
to mS. They concluded that both cases of heterologous boost provided a significant number of
cells producing antibodies exclusively specific for the primary antigen.
These studies were quite beneficial to our understanding of the original antigenic sin
phenomenon. However, questions about the genetic based mechanisms, for instance, which stage
in the generation of immunological diversity is responsible for this phenomenon, and how the
memory B-cell population elicited to one epitope is used during subsequent immune responses to
other structurally related epitopes, remain unsolved. Some of the questions were answered after
the development of hybridoma technology and recombinant DNA and DNA sequencing
technologies.
2.2.3. Molecular Analysis of "Original Antigenic Sin".
Manser and his colleagues have extensively studied the evolution of an antibody variable
region structure during immune response using p-azophenylarsonate (Ars) as a hapten.3 0 To
directly examine how the memory B-cell population elicited to one epitope might be used during
subsequent immune responses to other structurally related epitopes, the Manser group explored the
phenomenon of original antigenic sin at the molecular level.13 It is known that the secondary
immune response of strain A/J mice to protein conjugates of Ars often includes antibodies that
share a major idiotope and that are encoded by a single combination of variable gene segments
(VHIdCR). p-Azophenylsulfonate (Sulf), which is a structural analog of Ars, was incapable of
eliciting antibodies encoded by the same VHIdCR upon Sulf-homologous immunization.
Furthermore, the poor cross-reactivities of anti-Ars antibodies for Sulf and of anti-Sulf antibodies
for Ars were observed. Thus, characterization of the structure of the original antigenic sin
antibodies, encoding the VHIdCR gene (as a tag), generated by heterologous immunization should
be able to provide new insight into the above question, and thus, how the immune history of an
animal influences its immune status.
35
The "antigenic sin" antibodies were derived from mice that were immunized with Ars and
were rested for an extended period (up to 6 months) before receiving a booster injection with Sulf.
Most of the canonical "antigenic sin" antibodies, expressing VHIdCR gene segments, bind to Ars
with relatively high affinity, and with greater affinity than they bind to Sulf. However, a few
canonical "antigenic sin" antibodies were also found to preferentially bind Sulf over Ars. The
characterization of the structure of the genes encoding these antibodies revealed that (1) the Ars-
induced memory B-cell population capable of being cross-reactively stimulated by Sulf is largely
formed from a small fraction of somatically mutated V regions, and (2) the antibody repertoire and
clonal composition of this population are stable over long periods of time.
Following this report, Wysocki et al. hypothesized that if the above (1) was true, it should
be possible to recruit memory B-cells with varied antigenic specificities in vivo by simply
delivering a booster injection with Sulf during the primary immune response of Ars wherein the
somatic mutations to Ars have not occurred. 31 This hypothesis appeared to be verified by the
authors' succeeding in the exclusive alteration of specificities to the secondary antigen.
Furthermore, the translated sequences of the V genes of six out of the seven antibodies revealed
that they share an unusual somatic mutation that had never been observed in over 80 sequences of
conventional anti-Ars antibodies encoded by the VHIdCR gene segment: An asparagine to serine or
threonine replacement in position 35 of the VH region occurred. In contrast, the anti-Ars canonical
"antigenic sin" antibodies studied by Manser et al. uniformly lacked serine or threonine
replacements at position 35 in the VH region.30 These observations have led to the conclusion that
the conserved mutations at position 35 appeared to be strongly selected by unique somatic
mutations. The importance of these mutations was recently confirmed by Margolies et al. who
observed that the introduction by site-specific mutagenesis of serine or threonine residues at
position 35 into canonical antibody conferred a switch in specificity from Ars to Sulf. 32 Thus,
highly specialized mutant clones that would be otherwise excluded from the memory compartment
have been recruited into the memory pool by delivering booster injections with Sulf during the
primary immune response. This basic difference between the two sets of "antigenic sin" antibodies
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supports the idea that the somatic mutation process may be active only during stimulation in the life
of a B-cell clone.
In summary, studies of "original antigenic sin" at the genetic level have shown that (1)
memory B-cells capable of responding secondarily to a cross-reactive antigen express somatically
mutated V regions of antibodies, and (2) by controlling the timing of immunization, antibodies may
be generated which bind exclusively to the secondary antigen owing to unique somatic mutations.
2.2.4. Remarks
The literature survey of "original antigenic sin" clearly indicated that heterologous
immunization with two cross-reacting antigens is capable of inducing antibodies that bind either
and both antigens. Although phenomena of original antigenic sin upon heterologous immunization
have been often observed, the situations seemed to be greatly dependent on the antigen structure as
well as the immunization conditions employed. Nevertheless, we felt that the strategy of
heterologous immunization might provide a potential means to generate catalytic antibodies with
multiple catalytic residues.
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Chapter 3
Catalytic Antibodies elicited via Homologous and Heterologous Immunization
3.1. Hapten Design
In the context of heterologous immunization to generate multiple catalytic residues in the
antibody combining site, the design of two functionally different haptens is of prime importance.
These haptens must share a common chemical structure to crossreactively induce the immune
response, but each must also have a positive or negative haptenic charge. An appropriate isosteric
tetrahedral geometry (in lieu of the carboxylic ester/amide moiety to be hydrolyzed) is an additional
requirement. We have designed two structurally related haptens H5 and H2 with the goal of
generating antibody catalysts to hydrolyze ester SE and amide SA. Both haptens also share
common structural features with SE and SA differing only in the moiety containing the scissile
bond present in these substrates. Therefore, analogous pairs of haptens should be readily
applicable to hydrolytic cleavage of many other ester and amide substrates.
Structure of Haptens (H5 and H2) and Substrates.
HN, 02 N 1:1 jp , W+
M 02N N Rr~
H5a R = N-hydroxysuccimide H2a R = N-hydroxysuccimide
H5b R= OH 12b R = OH
02N N OHH
SE X=O
SA X=NH
Hapten H5 contains a 1,2-amino alcohol functionality and is designed to have the
following two features: (1) The quaternarized ammonium salt acts as a positive charge to generate a
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basic residue in the antibody combining site and also creates an empty cavity for the incoming
water molecule, likely to play a role of steps 1 and 3 in aspertic protease catalysis (see Chapter 1),
and (2) the hydroxy group represents the tetrahedral geometry to be analogous to the transition
state in step 2. Phosphonamidate transition state analog hapten H2 was originally designed by
Lerner and applied to generate catalytic antibodies for the hydrolysis of SE and SA. The negative
charged feature of phosphonate provides an opportunity to induce an acidic residue, interacting
with the oxyanionic transition state in step 2. Thus, the combining these haptenic features by
means of a heterologous immunization procedure should introduce both basic and acidic catalytic
residues into the antibody combining site without recourse to a complex bi-functional (zwitterionic)
hapten synthesis.
3.2. Synthesis of Hapten, Inhibitor, and Protein Conjugate
To obtain an immune response it is necessary to couple the hapten to a carrier protein, and
an appropriate linker with an activated group must be selected for this purpose. A conventional N-
hydroxysuccinimide-activated ester of a glutaric acid linker33 was chosen for both haptens H5a
and H2a to couple with lysine side-chains of a carrier protein.
Scheme 3. Synthesis of Hapten HSa.
R 0'b N 0 C
R.AN'CF3 N o' CF .
H H H
H
a . 52 R = CH20H 54 SS R CF3
53 R = CHO
0HN 3 02N N R .H
d r 55 R = CF3 57a R = (CH2)CO 2Me, R' = H 58a R = (CH2)3CO 2 Me
56 R = (CH2)3CO2 Me 57b R = (CH2) 3CO2Me, R' = TES 58b R = (CH2)3CO(N-hydroxysuccinimde)
(a) Dess-Martin periodinane, CH2 C12 , 86%; (b) p-NO2 PhCH 2P(OXOEt), NaH, 15-crown-5, THF, 62%; (c) m-CPBA, CH2C1 2, 99%;(dXi) NaBH4 , EtOH, (ii) CICO(CH2)3 CO2Me, Et3N, CH2C12 , 84%; (e)(i) NaN3, NH4 CI, acetone-HO2 0 (1:1); (ii) TESOTf,
2,6-lutidine, CH 2C12, 88%; (f)(i) Ph3 P, THF then H20, (ii) 37% CH20 in water, NaCNBH 3, MeCN, (iii) 5% HF in MeCN-H20,
51%; (g)(i) LiOH, t-BuOH-H 2 0 (2:1), (ii) EDC, N-hydroxysuccinimide, CH2C12, 67%, (iii) MeI, acetone, 42%.
Epoxide 55, which is a key intermediate of hapten H5a, was prepared in three steps from
alcohol 52 (Scheme 3). The oxidation of alcohol 52 was problematic; conventional methods such
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as Swern, PDC, and Collins oxidations provided low yields of aldehyde 53 with a substantial
amount of byproducts. However, the Dess-Martin periodinane oxidation34 proceeded well, the
formation of the side reactions presumably being suppressed under the mildly acidic conditions
employed. Coupling of 53 with diethyl p-nitrobenzylphosphonate, 3 5 readily derived from p-
nitrobenzyl bromide with ethyl phosphite, led to construction of the main skeleton of the haptens,
and the oxidation of olefmin 54 by m-CPBA yielded epoxide 55.
Hapten H5a was prepared in five steps from 55 (Scheme 3). Removal of the N-
trifluoroacetate protecting group with sodium borohydride followed by coupling of the resulting
aniline to the glutaric acid linker afforded epoxide 56. The regioselective epoxy-ring opening with
sodium azide and subsequent protection of the hydroxy group with triethylsilyl (TES) triflate
provided 57b. Reduction of the azide by triphenylphosphine (PPh 3),36 and reductive
methylation 3 7 of the resulting amine followed by deprotection of the TES group provided N,N'-
dimethylamino alcohol 58a. Hydrolysis of the methyl ester in the linker, conversion of the
resulting acid to the N-hydroxysuccinimide ester 58b, and finally treatment with methyl iodide
completed the synthesis of hapten H5a. For inhibition studies, hapten H5b containing a free
carboxylic acid terminus in the glutaryl linker group was chosen due to its enhanced water
solubility. The quaternarization of amine 58a followed by hydrolysis of the methyl ester afforded
inhibitor H5b.
Scheme 4. Synthesis of Hapten H2a
EtO. b C N 0 d
EtO' '"0 EtNH NHR 02N N o
S9a R = H 60a R = COCF 3 61a R = OH59b R = COCF 3 60b R=H 61b R = N-hydroxysuccinimide
(a) (CF3CO)20, Et3N, CH2C12, 96%; (bXi) PCI5, CHC1 3; (ii)p-nitroaniline, DMAP, pyridine, 86%; (iii) NaBH4, EtOH, 100o%;(c)(i) glutaric acid, pyridine, 77%; (ii) N-hydroxysuccinimde, DCC, DMF, 92%; (d) TMSI, NaI, CH 3CN, 92%.
Hapten H2a and inhibitor H2b were synthesized by a route similar to that previously
published by Lerner et al. (Scheme 4). Although Lerner used inhibitor H2c bearing
trifluoroacetate group in the linker, we selected H2b with a glutaric acid linker rather than H2c, in
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order to be consistent with the chemical structure between the two inhibitors H5b and H2b, as
well as with the substrates SE and SA.
Thus obtained, the haptens H5a and H2a were individually coupled with bovine serum
albumin (BSA) and bovine plasma fibrinogen (Fib). The protein conjugates BSA-H5 and BSA-
H2 were used for immunization, and Fib-H5 and Fib-H2 were used for screening.
3.3. Homologous and Heterologous Immunization
We have carried out two separate strategies of immunization. In the first, an animal is
immunized with three successive injections of BSA-H5 (homologous immunization). In the
second, an animal is immunized with two injections of BSA-H5 followed by an injection of BSA-
H2 (heterologous immunization). Comparison between the two different sets of antibodies
generated should reveal distinctive effects of these immunization strategies upon the generation of
catalysts.
Four Balb/c mice (mouse #21-24) each received a subcutaneous injection of 100 gg of
BSA-H5 emulsified in RIBI adjuvant (MPL and TDM emulsion), and the same injection of BSA-
H5 was given two weeks later. Seven days following the second injection, anti-serum titers for
IgG molecules were analyzed by an enzyme-linked immunosorbent assay (ELISA), and in each
case strong immune responses against Fib-H5 were observed (titers over 1:12,800) whereas poor
crossreactivities against Fib-H2 were observed (titers smaller than 1:800). This result indicates
that the immunization of animals with only H5 is incapable of inducing a large population of IgG
antibodies which tightly bind to H2.
In the case of homologous immunization, three weeks after the second injection, one of the
four mice (mouse #23) were again immunized with BSA-H5 using the same procedure. In the
case of heterologous immunization, seven weeks after the second injection, one of the other mice
(mouse #24) received a subcutaneous injection of 100 gg of BSA-H2 emulsified in RIBI adjuvant.
3.4. Antibody Production
Three days following the last boost, the spleens were harvested and the cells fused with 5
x107 653/HGPRT- myeloma cells to prepare hybridomas. Cells were plated into 6 (homologous
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injection) or 8 (heterologous injection) 96-well plates; each well contained 100 pL of HAT-DMEM
with 20% fetal bovine serum and 1% hybridoma enhancing supplement (Sigma).
After two weeks, the plates were analyzed by ELISA for binding to Fib-hapten conjugate.
In the case of homologous immunization fusion, supernatants from 96 wells were positive for
binding to Fib-HS; of these 10 were crossreactive to Fib-H2. In the case of heterologous
immunization fusion, 202 positive wells were observed. Of these, supernatants from 122 wells
bound to both haptens; 32 and 48 wells were entirely specific for Fib-H5 and Fib-H2,
respectively. All positive colonies were subcloned two or three times, after which 48
(homologous) and 50 (heterologous) monoclones remained active. All cell lines were individually
injected into pristane-primed Balb/c mice to generate ascites. The harvested ascites were treated
with ammonium sulfate (45% final concentration). The precipitated antibodies were dissolved in
50 mM TrisoHC1, pH 7.8 and dialyzed prior to chromatographic purification.
DEAE-Sephacel anion-exchange chromatography was performed by salt gradient (from 0
mM to 500 mM NaC1 in 50 mM Tris.HCl, pH 7.8). The fractions containing antibody (confirmed
by SDS-polyacrylamide gel electrophoresis) were then subjected to protein G-Sepharose affinity
chromatography (loaded on in 20 mM potassium phosphate, pH 7.2 and eluted with 100 mM
glycineoHC1, pH 2.7) to yield purified antibody (>95% by SDS-polyacrylamide gel
electrophoresis).
Homologous immunization with H5 produced 48 monoclonal antibodies having strong
affinities to H5 while only five antibodies among them bound weakly to H2, as expected (Figure
1A). In contrast, heterologous immunization provided 50 monoclonal antibodies with varied
affinities for H5 and/or H2 (Fig. 2A).
3.5. Control Experiments
To confirm the reproducibility of the heterologous immunization approach, we employed
an immunization protocol identical to that described above with two additional mice (the first one
was used by H. Suga at MIT; and the second by T. Tsumuraya at Kao Basic Research Institute,
Japan). Anti-serum titers to both haptens were measured. In the both cases, seven days after the
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last injection with BSA-H2, high titers to both Fib-H5 (1:12,800) and Fib-H2 (1:12,800) were
observed. These results demonstrate the reproducibility of the cross immune response observed in
the animals subjected to this protocol, as well as the reproducibility of the production of IgG
antibodies binding to both haptens in anti-serum.
Subsequently, we examined the production of monoclonal antibodies by the single
immunization protocol using H2 (where an animal was immunized with BSA-H2 and at day 3
hybridomas were prepared; two mice were examined). This experiment should tell us whether the
antibody production observed in heterologous immunization was simply the result of the primary
immune response by H2 or not. A total of 11 hybridomas producing positive binders to Fib-H2
were cloned. All of the antibodies exhibited very weak affinity (presumably Kds > 10-3 M) to H2
and were found to be IgMs, the antibody subclass typically induced by primary response. This
result is in contrast to the observation that all antibodies isolated in the heterologous immunization
procedure were found to be IgGs. These experiments indicate that the production of antibodies via
heterologous immunization is not likely the result of the stimulation of naive B-cells by H2, but
probably result from the unique stimulation of H5-primed memory B-cells to produce a large
population of IgG molecules binding strongly to one or both haptens H5 and H2.
In addition, the heterologous immunization protocol was carried out in the reverse order of
the haptens, where an animal was immunized with BSA-H2 twice followed by BSA-H5.
Although we immunized five mice and prepared hybridomas, only two fusions successfully
provided a total of 8 monoclones producing positive binders to the haptens. While all antibodies
produced exhibited weak affinities to the haptens (KdS > 10-3 M), four of them bound H2, three
bound H5, and one bound both the haptens. Furthermore, all these antibodies were found to be
IgMs, indicating that the production of antibodies should be the result of the primary immune
response by H5. Thus, the phenomenon of the cross immune response against haptens H5 and
H2 was observed only when the heterologous immunization protocol in the order of H5 followed
by H2 was employed.
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3.6. Hydrolytic Assay of Monoclonal Antibodies
Catalytic activities of the monoclonal antibodies were initially screened using the ester
substrate SE in a buffered solution at three different pH's (50 mM Mes, 80 4M NaCl, pH 6.2; 50
mM KPi, 80 FM NaCl, pH 7.0; or 50 mM Tris.HC1, 80 pM NaCl, pH 7.8) by monitoring the
production of the p-nitrophenolate ion. In the case of homologous immunization, seven antibodies
proved catalytic, and their activities were effectively inhibited by the addition of free hapten H5b.
It should be noted that all catalytic antibodies were specific to hapten H5b and none of
crossreactive antibodies to hapten H2b exhibited catalytic activity (Fig. 1B). Michaelis-Menten
parameters (kcat, catalytic rate constant; Km, Michaelis constant) of three representative catalytic
antibodies at pH 7.8 (50 mM Tris-HC1, 80 p.M NaCl) are shown in Table 1A. The rate
accelerations (kcat/kun where kun is the zero-buffer background hydrolysis rate constant of ester
SE) were found to be -103. Inhibition constants (Ki) of inhibitor H5b or H2b to three
representative catalytic antibodies (H5-38, H5-25, and H5-67) were also determined in the
presence of three various concentrations of inhibitor (Table 1A). All of these catalytic activities
were strongly inhibited by the addition of H5b (the observed Ki's are smaller than 5 p.M) whereas
none of the catalysts was inhibited by the addition of H2b, as expected. These results indicate that
catalytic antibodies generated by homologous immunization of hapten H5a are highly specific to
only the hapten employed.
In the case of heterologous immunization, 19 monoclonal antibodies out of 50 accelerated
the hydrolysis of ester SE (Fig. 2B). Nine of these had significantly higher catalytic efficiencies
(kcat/kun > 104) than those derived from the homologous immunization protocol. Interestingly, the
majority of catalytic antibodies possessed similar crossreactivities to haptens H5b and H2b (Fig.
2B), and these catalytic activities were effectively inhibited by both haptens. These results strongly
suggested that heterologous immunization greatly contributed to the enhancement of antibody
catalytic activity and that most of the catalysts isolated likely have catalytic sites interacting with
both functionalities of the haptens. Inhibition constants (Ki) of three representative antibodies
(H5H2-42, H5H2-187, and H5H2-108) with H5b or H2b were determined and the results are
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shown in Table 1B. The catalytic activities of two antibodies (H5H2-42 and H5H2-187) were
effectively inhibited by both haptens although the Ki's were not as small as those observed in
catalytic antibodies obtained by homologous immunization. Inhibition of the catalytic activity of
antibody H5H2-108 was only observed in the presence of H2b, while this antibody was found to
weakly associate with H5b in a competition ELISA experiment (vide infra).
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Figure 1. Distributions of antibodies (A) and catalytic antibodies (B), generated
by homologous immunization protocol, versus the dissociation constants (Kd) of
free hapten H5b and H2b. The Kd of each hapten was determined by competition
ELISA.
46
Number of
Antibodies
e.
0
>1
>1
V a)O _
Number of
Antibodies W
UO
r>1
>1
A Ien °x 
· ' o
0 
Figure 2. Distributions of antibodies (A) and catalytic antibodies (B), generated
by heterologous immunization protocol, versus the dissociation constants (Kd) of
free hapten H5b and H2b. The Kd of each hapten was determined by competition
ELISA.
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3.7. Antibody Binding and Specificity
A total of 12 antibodies including the above three catalytic antibodies (whose kinetics had
been elucidated) and three noncatalytic antibodies were selected from the pool of monoclonal
antibodies elicited via each immuniztion, and their dissociation constants (Kd) with the two haptens
(H5b and H2b), amide SA, p-nitrophenol (PNP), and the product acid were determined. These
deta enabled us to evaluate the influences of the two different immunization strategies on the
characteristics of the entire set of antibodies.
The following three comments are appropriate for the measurement of Kds. (1) We
measured Kds by the modified procedure of the competition ELISA, originally described by
Friguet et al.38 Antibody and inhibitor were equilibrated for a short time period (30 min) prior to
running the competition ELISA. Therefore, the Kd observed is not necessarily the absolute Kd of
antibody with inhibitor. However, Kds obtained after 1 h equilibration are normally close to those
obtained after 30 min. Under our conditions, since Kds were measured under identical conditions
in all experiments, Kds for each antibody-inhibitor pair could be compared directly. In particular,
the comparison of antibody binding to substrate versus products (PNP and the product acid)
indicates the degree of product inhibition for a given antibody under the kinetic assay conditions.
(2) Due to difficulties in the accurate measurement of the Kds of ester SE for catalytic antibodies,*
we determined the Kds of the stable amide SA instead. We believe that the Kds of amide SA
should approximate those of ester SE. In fact, the Kds of SA for noncatalytic antibodies were
found to be almost identical with those of SE (examples shown in Table 1A). (3) Although the
Kds of larger than 10-3 M could only be approximated due to the difficulty of making precise
measurements, the values reported were at least duplicated, confirming their consistency.
In total, Kds of twelve antibodies with the respective inhibitors were determined by the
competition ELISA procedure. The results are summarized in Table 1.
* The antibody-catalyzed hydrolysis of SE proceeds substantially within 30 min.
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Both classes of antibodies (catalytic and noncatalytic) induced by homologous
immunization bind tightly to H5b (Kds < 3 x 10-5 M) but crossreact poorly with H2b (Table 1A).
On the other hand, antibodies raised by heterologous immunization exhibit diverse binding
behavior to H5b and H2b (Table 1B), as also seen in Figure 2. In contrast, the Kds of all
antibodies studied with amide SA were found to be similar, lying in the range of 10-4- 10-3 M,
despite the significant difference observed in catalytic activity between the antibodies derived by
homologous immunization and those derived by heterologous immunization. The Kds of
antibodies for PNP are relatively varied (10-1-10-3 M) but generally 102-103 times higher than
those for SA. The Kds of the product acid were too weak to be detected by competition ELISA
within its solubility limit (20 mM). These observations indicate the absence of fetal product
inhibition for the catalysis of antibodies during kinetic experiments. It is also noted that, in the KdS
of SA and the products, no significant differences between catalytic and noncatalytic antibodies
were observed.
These observations have led to two significant conclusions. First, heterologous
immunization did not alter the ability of the antibodies to recognize the ground state molecules, but
instead greatly enhanced their catalytic efficiencies, presumably by the participation of additional
catalytic residues. Second, noncatalytic antibodies recognize the substrate and products with Kds
comparable to catalytic antibodies, demonstrating that their lack of catalytic activity is due neither to
insufficient substrate binding nor strong product inhibition, but more likely to lack of appropriate
catalytic residues in the active site.
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3.8. Characterization of Antibody H5H2-42
Antibody H5H2-42, the best catalyst obtained by heterologous immunization, was selected
for further study. The saturation behavior of antibody H5H2-42 is consistent with Michaelis-
Menten kinetics, and a Lineweaver-Burk analysis at pH 7.0 (50 mM Pipes, 80 IM NaCi) gave
apparent values for kcat and Km of 12.5 min-1 and 240 pIM, respectively (Fig. 3). The observed
rate acceleration (kcat/kun, where kun = 1.8 x104 min-1) at pH 7.0 was 6.8 x 104 (Table 1B). It is
noted that the kcat of 11.0 min-1 was observed at pH 6.6 (kun = 7.4 x 10-5 min-1), resulting in a
rate acceleration of kcat/kun = 1.5 x 105 (the parentheses in Table 1A). This rate acceleration is
approximately two orders of magnitude greater than that observed for the representative catalytic
antibody H5-67 derived from the homologous immunization of H5a.
O No Inhibitor
A [H5b] = 0.50 mM
O [H2b] = 0.10 mM
U. -
0.5-
'g 0.4-
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0 1 2 3 4
1/[SE] (mM'1 )
Figure 3. Lineweaver-Burk plot for hydrolysis of ester
SE by 0.6 pgM of H5H2-42 antibody in the presence and
absence of hapten inhibitors (H5b and H2b) at pH 7.0.
The catalyzed reaction was competitively inhibited by the addition of free hapten H5b or
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H2b, and the inhibition constants (Ki) for each hapten were determined at pH 7.0. Lineweaver-
Burk plot analysis (Fig. 3) indicated that the Ki's for H5b and H2b are 300 p.M and 22 gM,
respectively. Dixon plot analysis (Fig. 4A and Fig. 4B) resulted in Ki's of 525 ( 25) gM and 30
(+ 5) gM, respectively. These results strongly suggest that catalytic residues in the active site of
O [SE] = 0.25 mM
O [SE] = 0.50 mM
O [SE] = 1.0 mM
A [SE] = 2.0 mM
O [SE]
O [SE]
O [SE]
A [SE]
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H5b (M)
750 1000
6
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. 3
E
1
0
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Figure 4. Dixon plot for hydrolysis of ester SE by 0.6 gM of H5H2-42 antibody
in the presence of hapten inhibitors H5b (A) and H2b (B) at pH 7.0.
antibody H5H2-42 interact with both functionalities of the haptens, while the antibody binds more
tightly to secondary antigen H2b rather than to primary antigen H5b. It is also noteworthy that no
significant product inhibition was observed during the hydrolysis of SE (with greater than 500
actual turnovers) unlike some previously reported catalytic antibodies raised to a phosphonamidate
hapten H2a alone. The lack of product inhibition is consistent with the dissociation constant
measured with PNP and the product acid.
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The dependence of the kinetic parameters (kcat and Km) upon the nature of the buffer was
also studied. Apparent values of kcat and Km in 50 mM Pipes, 80 ptM NaCl, pH 7.0 were
determined to be 12.5 min-1 and 240 gM, respectively (Table 1B), while in 32.5 mM Pipes, 80
p.M NaC1, pH 7.0 these were 12.3 min-1 and 109 [tM, respectively (Fig. 5). In the three
component buffer MHD (12.5 mM Mes, 12.5 mM Hepes, and 25 mM diethanolamine), used for
pH-dependent kinetics (vide infra), these were determined to be 12.2 min- 1 and 83 M,
respectively. Thus, the parameter kcat does not depend on the nature of buffer species but Km was
o 50 mM PIPES, 50 mM NaCI
O 50 mM PIPES, 80 pM NaC1
0 32.5 mM PIPES, 80 pM NaCI
I-§
017:F-
=L
0 0.5 1 1.5 2 2.5
1/[SE] (mM '1)
Figure 5. Lineweaver-Burk plot for hydrolysis of ester SE by
0.5 p.M of H5H2-42 antibody in vaious buffer media at pH 7.0.
lower when the buffer-concentration was decreased. On the other hand, the concentration of NaCl
changed both parameters; in 50 mM Pipes, 50 mM NaC1, pH 7.0 the apparent values of kcat and
Km were 10.1 min-1 and 309 p.M, respectively (Fig. 5). The Lineweaver-Burk plot in Fig. 5
illustrates that NaCl likely behaves as an noncompetitive inhibitor. This might be attributable to
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association of sodium or chloride ion or both to catalytic group(s) in the antibody active site,
resulting in inhibition of the catalytic functions.
The study of pH-dependent steady-state kinetics often provides useful information
regarding a reaction mechanism involving the titration of a group at the antibody binding site
whose dissociation promotes substrate hydrolysis. We have examined steady-state kinetics over
the pH range 6.2 to 8.5 and determined the first- and second-order rate constants, kcat and
kcat/Km. The pH dependence of kcat and kcat/Km should follow the pKa (ionization) of catalytic
residues extant in the antibody-substrate complex and in the free antibody, respectively.3 9 The
plots of pH vs logkcat and pH vs logkcat/Km are illustrated in Fig. 6.
A logkcat
O logkcat/Km
2.5-
to 2-
o
0o
1.5-
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o
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6 6.5 7 7.5 8 8.5
pH
Figure 6. pH-Ddependent steady-state kinetics. Assays
were performed in MDH buffer (12.5 mM Mes, 12.5 mM
Hepes, 25 mM diethanolamine) for the entire pH range.
These results reveal that (1) the antibody-catalyzed hydrolysis of SE is virtually independent of the
hydroxide ion concentration, and (2) a functional group with a pKa of -7 appears to exist in the
catalytic site. These observations are in contrast to those reported for the hydrolytic antibody
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NPN43C9 induced to H2a alone, in which the antibody-catalyzed hydrolysis of SE was found to
be hydroxide ion-dependent up to pH 9 and the apparent pKa of the catalytic site was determined to
be -9. These significantly different characteristics may result from the fact that the functions of
catalytic residue(s) generated by heterologous immunization of H5a and H2a differ from those
generated by homologous immunization of H2a. The amide bond of SA was, however, cleaved
very slowly by antibody H5H2-42 at neutral pH (kcat was roughly determined to be -10-4 min-1
although the conditions for optimum catalysis in this system remain to be elucidated), whereas
antibody NPN43C9 was reported to catalyze the hydrolysis of SA at pH 9 with kcat = 0.08 min- 1.
3.9. Conclusions
It has been shown that antibodies generated by heterologous immunization have significant
esterase activity. Nevertheless, the generation of amidase antibodies, our ultimate goal, has not yet
been attained. We believe, however, that elaboration of hapten design combined with the
heterologous immunization strategy will produce catalytic antibodies more efficient than those
obtainable via the conventional immunization protocol. Our extensive analysis of catalytic
antibodies induced to haptens with a 1,2-amino alcohol functionality (see Chapter 4) demonstrated
that hapten H6 bearing a simple ammonium salt (-NH 3+) provided the highest probability of
finding the esterolytic catalysts whose catalytic activities were comparative to those generated by
H5. A heterologous immunization protocol employing H6 and H2 is likely to induce catalytic
antibodies with much higher probability. This in turn would provide a higher chance of isolating
an efficient catalysts for the cleavage of amide SA. In more general terms, the combined strategy
of using synthetic haptens, each containing a different charge, in conjunction with the heterologous
immunization protocol, should provide a powerful tool for generating antibodies with a wide
variety of different catalytic specificities and activities.
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Chapter 4
Esterolytic Antibodies Induced to Haptens with a 1,2-Amino Alcohol
Functionality
4.1. Introduction
The design of haptens contributes the most important step towards the preparation of
efficient antibody catalysts. As described in Chapter 3, we have designed and used two haptens
H5 and H2, each containing a positive or a negative charge, for a heterologous immunization
strategy, and this strategy has successfully generated antibody catalysts superior to those generated
by homologous immunization using H5. However, the catalysts obtained were still not active
enough to efficiently cleave the amide bond. The negatively charged phosphonamidate hapten H2
is generally accepted as an ideal transition state analog and proved to be a good hapten for the
generation of catalytic antibodies. In contrast, the design of positively charged haptens such as H5
has not been optimized for the generation of catalysts. To obtain a more ideal positively charged
hapten, we have synthesized a series of haptens H5, H6, and H7 with a 1,2-amino alcohol
functionality and generated antibodies to hydrolyze ester SE. In order to critically evaluate these
hapten designs and begin to understand the rules for imparting catalytic sites to antibodies, our
studies have been extensive and have encompassed complete sets of monoclonal antibodies raised
to each of the haptens H5-H7. This work was done in collaboration with Mr. Oguz Ersoy, Dr.
Takeshi Tsumuraya and Dr. Jung Lee.40
4.2. Hapten Design
In an effort to understand the rules for generating catalytic antibodies from haptens, we
designed three structurally related haptens H5-H7, all of which contain a 1,2-amino alcohol
functionality. The design is based on the reaction mechanism described previously for the aspartic
protease-catalyzed amide hydrolysis (Chapter 1). Hapten H6 has similar features to H5: (1) the
protonated primary amine in H6 act as positive charges to generate a basic residue in the antibody
combining site, and also an empty cavity for the incoming water molecule. (2) The secondary
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Haptens, Inhibitors, and Substrates.
No 
0 0
0 2N N R
H5a R = N-hydroxysuccinimide
H5b R = OH
0 0
H0 2N
OH
H7a R = N-hydroxysuccinimide
H7b R = OH
NH 2
0 2N N RH
H6a R = SH
H6b R = CH2COOH
0 0
02N N 'JL) K OHH
SEX=O
SA X = NH
hydroxy groups in H6 represent the tetrahedral geometry required to stabilize the transition state.
In addition to feature (2), 117 carries an additional negatively charged phosphate group attached to
the hydroxyl moiety to induce an additional acidic residue, to further stabilize the oxyanion
transition state. It is noted that the straight replacement of the ester/amide moiety in substrate SE
with the simple 1,2-amino-alcohol functionality provides the structures of haptens H115-117. The
application of these hapten design should not, therefore, be limited to the hydrolysis of substrate
SE but can be extended to that of many other substrates. Although it has been reported that some
catalytic antibodies were relatively flexible to substrate variations, we were concerned at the outset
that the functional groups in haptens H5 and 117 would place the catalytic residues too far from the
reaction site (misfit). Nonetheless, it is important to learn the extent to which the structural
mismatch between hapten and substrate influences both catalytic activity and binding ability to the
substrate and the products.
57
'N,- 
4.3. Linker Selection, Hapten Synthesis, and Protein Conjugation
A conventional N-hydroxysuccinimide-activated ester of a glutaric acid linker was chosen
to couple haptens H5a and H7a to lysine residues of a carrier protein.3 3 However, since the
primary amino group of hapten H6 could undergo self-coupling with this activated ester, a
different linker bearing a free sulfhydryl group was selected. In this way, hapten H6a could be
selectively coupled to maleimide-modified lysine residues of carrier proteins without temporary
protection of the primary amine.41
Scheme 5. Synthesis of Hapten H6a.
N3 N3
a b o c
55 02N NH2 02 oN). S H6a
62 63
(a)(i) NaN 3, acetone-H20 (1:1), (ii) K2CO3, MeOH-H2 0 (1:1), 62%; (b) 3,3'-dithiodipropionic acid,
bis(N-hydroxysuccinimide)ester CH2C12, 55%; (cXi) Ph3P, THF, then H20, 70%; (ii) DTT, cat. Et3N, CH2C12, 77%.
Scheme 6. Synthesis of Hapten H7a.
N3 N'
05 2 N NIR V d H7MoO-P H 0 2 NN RH7aOMe MeO-PO H
OMe )OMe
64 R = (CH2 3CO2Me c 65 R = (CH2)3CO 2 Me
66 R = (CH 2 )3CO(N-hydroxysuccininimde)
(a)(i) (MeO)2PN(Et)2, 1H-tetrazole, THF (ii) m-CPBA, CH2C12, 80%o; (b)(i) HS(CH2)3SH, Et3N, MeOH, (ii) 37%CH20 in water, NaCNBH 3, MeCN, 45%; (c)(i) LiOH, t-BuOH-H20 (2:1.5), (ii) EDC, N-hydroxysucciiimide,
CH2C12, 65%; (d)(i) Mel, acetone, 54%, (ii) TMSI, MeCN, 70%.
Synthesis of H5a was described previously (Scheme 3). Synthesis of haptens H6a and
H7a are shown in Scheme 5 and Scheme 6 respectively. For inhibition studies, haptens H5b,
H6b, and H7b, each containing a free glutaric acid linker, were chosen due to their enhanced
water solubility. Prior to coupling with hapten H6a, the carrier proteins bovine serum albumin
(BSA) and bovine plasma fibrinogen (Fib) were individually modified with the N-
hydroxysuccinimide ester of 3-maleimidepropionic acid.41 c The reaction of the resulting
maleimide-BSA and maleimide-Fib conjugates with hapten H6a afforded the corresponding BSA-
H6 and Fib-H6 conjugates, respectively. Although BSA-H6 remained in buffer solution during
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its preparation, Fib-H6 precipitated. Therefore, we decided to use BSA-H6 for screening (see
below) and Fib-H6 for immunization. In contrast, the coupling of hapten H5a and H7a
containing N-hydroxysuccinimide activated esters with BSA and Fib both yielded solutions of
BSA- and Fib-hapten conjugates which were used for immunization and screening, respectively.
4.4. Antibody Production
Four Balb/c mice were immunized with the protein-hapten conjugate Fib-H6. After two
injections of this conjugate, serum immunoglobulin G (IgG) was titrated against the BSA-H6
conjugate by means of an enzyme-linked immunosorbent assay (ELISA). The mouse with the
highest titer (1:12,800) was subsequently boosted, and three days later its spleen was taken for the
preparation of hybridomas.4 All IgG-producing hybridomas that bound to the BSA-H6 conjugate
were subcloned two or three times, to yield a total of thirty-four (34) cell lines producing
monoclonal antibodies. In the same manner, immunization with BSA-H5 and BSA-H7 produced
48 and 20 monoclonal cell lines, respectively. All clones were individually propagated in ascites to
obtain milligram quantities of monoclonal antibodies, which were purified by salt precipitation,
anion-exchange, and affinity chromatography.
4.5. Antibody Binding and Specificity
To evaluate the structural influence of the hapten on antibody binding and specificity, three
representative catalytic antibodies and three noncatalytic antibodies were chosen from each group
of antibodies induced to haptens H5-H7 (a total of 18 antibodies), and their dissociation constants
(Kd) with their respective haptens, SA, PNP, and the product acid were determined (Table 2).
As expected, the Kd values of the antibodies with their respective haptens indicated tight
binding. These Kds lie in the range of 10-7-10 -5 M which is typically observed for antibody-
antigen binding. Subsequently, the affinities for substrate were evaluated by the measurement of
Kd using amide substrate SA. Most of the antibodies elicited to haptens H5 and H6 exhibited Kds
of roughly 10-3-10-4 M for amide SA, while the antibodies generated by hapten H7 generally
displayed affinities about 10-fold lower, supposedly due to the large structural and electronic misfit
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between hapten H7 and amide SA. In contrast, SA showed similar affinity to both catalytic and
to noncatalytic antibodies.
Finally, dissociation constants of the antibodies were measured for the two products, p-
nitrophenol (PNP) and the product acid. As described in Chapter 3, these constants are indicative
of the degree of product inhibition during hydrolysis, which has often limited the number of
turnovers achieved by antibody catalysts in the past.6- 9 The affinity of antibodies in all three
groups to PNP were found to be relatively weak, lying in the range of 10-2-10-1 M, in sharp
contrast to previously reported antibodies. 6 a,7 In an effort to measure the Kds for the product acid,
we found that the affinities of antibodies induced to haptens H5 and H6 were too weak to be
determined within the solubility limit of this acid (20 mM). On the other hand, antibodies elicited
by hapten H7 weakly associated with the acid and had Kds in the 10-2-10-1 M range, which would
account for that an amino acid residue complementary to the negative-charged phosphate in H7
interacts with the carboxylate of the product acid. It should be noted that the antibody-Kds with
PNP and the product acid were generally 102 to 103 times higher than those with SA, indicating
the absence of significant product inhibition during the hydrolysis of SE. Also, the affinities of
the catalytic antibodies to these products were again similar to those of the noncatalytic antibodies.
The above studies show that the Kd values of the antibodies generated by one hapten are
generally similar to each other regardless of whether they are catalytic or noncatalytic. This result
suggests that the lack of antibody catalytic activity is probably due neither to insufficient substrate
binding nor to product inhibition, but rather to an inappropriate placement of active site residues in
the antibody combining site. This conclusion is consistent with that obtained in Chapter 3 as well
as Janda's findings,2lb indicating that this conclusion may be generally valid in antibody catalysis.
4.6. Esterolytic Activity of Antibody
Antibodies (10 gM) were initially screened for their ability to catalyze the hydrolysis of
ester SE in a buffered solution (50 mM Mes, 80 gM NaCl, pH 6.2 and 50 mM TrisoHCl, 80 gM
NaCl, pH 7.8) containing 5% of organic cosolvent (4.8% acetonitrile and 0.2%
dimethylsulfoxide). The production of the p-nitrophenolate ion (absorbance observed at 405 nm)
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was monitored. Most of the catalytic antibodies found (8 from hapten H6, and all of them from
haptens H5 and H7) were further characterized and found to obey Michaelis-Menten kinetics for
the hydrolysis of SE. The first-order rate constants (kca) and Michaelis constants (Km) of three
representative catalytic antibodies (denoted by asterisk) from each group of antibodies raised to
haptens H5-H7 are shown in Table 2. The inhibition constants (Ki) of the catalytic antibodies for
inhibitors H5b-H7b were also determined and are listed in Table 2. All assays were performed at
25°C in 50 mM TrisoHCl, 80 gM NaCl, pH 7.8 containing 5% of organic cosolvent (4.8%
acetonitrile and 0.2% dimethylsulfoxide).
The initial screening for esterolytic activity identified as catalytic 7 out of the 48 antibodies
to hapten H5, 16 out of the 34 to hapten H6, and 4 out of the 20 to hapten H7. Significantly, all
three of the haptens based on the 1,2-amino alcohol design were able to induce esterolytic activity
in antibodies, although none of the antibodies isolated hydrolyzed the amide bond of SA with a
significant rate acceleration. The Michaelis-Menten parameters (kcat, Kmin, and Ki in Table 2) for
three representative catalytic antibodies derived from each of the three haptens revealed that all of
the catalytic antibodies analyzed could hydrolyze ester SE with a comparable rate acceleration,
kcat/kun lying between 1 x 103 and 3.3 x 103. It is interesting to note that although structural
variations in haptens H5-H7 alter the antibody specificities and affinities as shown in Table 2, no
significant changes in catalytic rate are induced.
The noticeable difference among the three groups of antibodies raised by haptens H5-H7
lies, however, in the probability of finding catalytic activity in the isolated monoclonal antibodies.
This probability was remarkably high when antibodies were elicited by hapten H6, reaching nearly
50%, whereas relatively low probabilities were observed with haptens H5 and H7. We speculate
that haptens H5 and H7 with a sterically demanding NMe3+ group (as compared to a NH 3+
group) elicit antibodies in which the complementary amino acid residue tends to be generated, in
the transition state of hydrolysis, away from the location of the carbonyl group of SE. The close
proximity of the amino acid residue to the carbonyl group appears to be important and can be more
readily achieved with the NH3+ group. Furthermore, the similar maximum rate accelerations
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observed with antibodies raised to haptens H5-H7 deserve some comments. The catalytic
efficiency was not enhanced by the introduction of an additional negatively charged phosphate
group in hapten H7. Although the phosphate group could induce an appropriate charge, it may be
too large to permit the induction of a catalytic residue in close proximity to the transition state
oxyanion. This interpretation, if correct, would lead to the tentative conclusion that the rate
enhancement attainable by antibodies raised to a singly charged 1,2-amino alcohol functionality
would be in the range of 103 as observed with haptens H5-H7. The present studies have
provided insight valuable to future hapten design; it is clear that the appropriate positioning of a
zwitterionic charge and the size of the inducing functionality are critical.
4.7. Perspectives
We have applied two methods, heterologous immunization with H5 and H2, and
homologous immunization with H5, H6, and H7, for generating catalytic antibodies with
hydrolytic activity. Both have been able to induce esterolytic antibodies with a rate acceleration of
103-105. However, cleavage of an amide bond seems to require that the rate enhancement of ester
hydrolysis achieved by catalytic antibodies must be at least 106. As discussed in 3.9, we believe
that heterologous immunization employing H6 and H2 is likely to induce catalytic antibodies with
much higher probability, which in turn would provide a higher chance of isolating more efficient
catalysts capable of cleaving the amide bond. The work concerning this issue is currently
underway.
Finally, a question is raised, and it is hoped to be answered at some point in the future.
Namely, will the generation of acidic and basic residues into an antibody prove to be a strategy
sufficient for the cleavage of the energetically demanding amide bond? Although aspartic proteases
catalyze peptide hydrolysis by using only the essential acidic and basic catalytic residues, some
"evolved" proteases actually use an additional feature such as a nucleophile (e.g. serine proteases)
or a metal co-factor (e.g. carboxy peptidases) in order to efficiently catalyze this chemical reaction.
Thus, such co-factors may likely be required to generate antibody catalysts with full-fledged
protease activity. To address this question, we are currently studying the design of haptens for
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generation of antibody catalysts via an acyl-migration mechanism. Our initial view is that
antibody-catalyzed amide hydrolysis might be designed to proceed via acyl migration using an
intramolecular hydroxyl nucleophile, where the reaction is assisted by acid-base catalysts provided
by the antibody. Such an approach should be able to provide important information for answering
the question.
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Chapter 5
Experimental Section
5.1. Synthesis of Hapten
5.1.1. General Methods
All reactions were carried out in oven-dried glassware under an atmosphere of argon.
Reactions containing water were run under an atmosphere of air. Column chromatography was
performed using 230-400 mesh silica gel (Merck). Proton ( 1H NMR) and phosphorus (3 1 p NMR)
magnetic resonance spectra were recorded at 300 and 60 MHz on a Varian XL-300 spectrometer,
respectively. The spectra were referenced to CDC13 (7.24 ppm), acetone-d6 (2.04 ppm), D 20
(4.67 ppm), or CD 30D (4.78 ppm). Data are reported as follows: chemical shift [multiplicity (s =
singlet, d = doublet, t = triplet, q = quartet, quint = quintet, m = multiplet, br = broad), coupling
constant (Hz), integration]. Infrared (IR) spectra were recorded on a Perkin-Elmer 283B
spectrometer. Melting points were not corrected. High-resolution mass spectra (HRMS) were
recorded on a Finnigan MAT 8200 spectrometer. Elemental analyses were performed by Desert
Analytics (Tucson, AZ).
5.1.2. Synthesis of Hapten H5a
2-[4-[(Trifluoroacetyl)amino]phenyl]ethan-l-ol (52). To a stirred solution of 4-
aminophenethyl alcohol (8.00 g, 58.3 mmol) and triethylamine (9.8 mL, 70.0 mmol) in CH2C1 2
(100 mL) was slowly added trifluoroacetic anhydride (8.60 mL, 61.2 mmol) at 0 'C, and the
mixture was allowed to warm to room temperature and was stirred for 1 h. The solution was
washed with saturated aqueous NaHC03 (30 mL) followed by brine (30 mL), and the organic
layer was dried over MgSO4 and concentrated under reduced pressure. The crude residue
crystallized upon trituration with CHC13, and the crystals, after filtration, were recrystallized from
CHC13 to afford 52 in 60% yield (8.16 g, 35.0 mmol) as colorless crystals: mp 129-131°C; IR
(CHC13) 3420, 1730, 1600, 1280, 1140 cm-1; 1H NMR (CDC13, 300 MHz) 7.44 (dd, J = 10.5
Hz, 2H), 7.14 (d, J = 10.5 Hz, 2H), 3.71 (t, J = 7.1 Hz, 2H), 3.20 (s, 1H), 2.75 (t, J = 7.1 Hz,
65
2H). Anal. Calcd for CldH10F3 NO2: C, 51.51; H, 4.32; N, 6.01. Found: C, 51.63; H, 4.32; N,
6.04.
2-[4-[(Trifluoroacetyl)amino]phenyl]acetaldehyde (53). To a stirred suspension of 5
(4.66 g, 20 mmol) in CH2C12 (200 mL) at -78 °C was added a solution of Dess-Martin periodinane
(10.0 g, 23.6 mmol) in CH2C12 (50 mL), and the resulting suspension was allowed to warm to
room temperature over a 1 h period with vigorous stirring. After 2 h, the reaction mixture became
an orange clear solution, and the solution was stirred for an additional 1 h. The resulting solution
was poured into a vigorously stirred saturated aqueous solution of NaHCO3 and Na2S203 (1/1,
100 mL), and the organic layer was washed with brine (50 mL), dried over MgSO4, and
concentrated. The residue was chromatographed (silica gel, 70/30 hexane/Et2O) to give a yellow
solid, and the solid was recrystallized from 50/50 CHC13/hexane to afford 53 in 84% yield (3.90
g, 16.8 mmol) as colorless crystals: mp 112-114 C; IR (CHC13) 3420, 2820, 1720, 1600, 1140
cm- 1; 1H NMR (CDC13, 300 MHz) 6 9.72 (t, J = 1.8 Hz, 1H), 7.88 (brs, 1H), 7.54 (d, J = 8.7
Hz, 2H), 7.22 (d, J = 8.7 Hz, 2H), 3.68 (d, J = 1.8 Hz, 2H). Anal. Calcd for C 1 0H 8F 3NO2 : C,
51.96; H, 3.49; N, 6.06. Found: C, 52.28; H, 3.44; N, 5.84.
3-[4-[(Trifluoroacetyl)amino]phenyl]-l-(4-nitrophenyl)-(E)-prop-l-ene (54). To a
stirred suspension of sodium hydride (80% in oil, 270 mg, 9.00 mmol) and a catalytic amount of
15-crown-5 (90 liL, 0.45 mmol) in THF (25 mL) at 0 °C was slowly added a solution of diethyl
(p-nitrobenzyl)phosphonate (2.56 g, 9.73 mmol) in THF (25 mL) over a 3-min period. A rapid
evolution of hydrogen started immediately, and the solution colored wine red during 30 min. To
this was added a solution of 53 (1.50 g, 6.49 mmol) in THF (25 mL) at 0°C with stirring, and the
resulting mixture was maintained at 0 C for 1 h to give a black precipitate. The reaction was
quenched with saturated aqueous NaHCO3, and the suspension was stirred until it became a clear
yellow solution. The resulting solution was washed with EtOAc (3 x 25 mL), and the combined
organic layers were washed with brine (50 mL), dried over MgSO4, and concentrated.
Purification of the residue through a short column of silica gel (70/30 hexane/EtOAc) provided a
solid which was recrystallized from 50/50 hexane/Et20 to afford 54 in 62% yield (1.41 g, 4.03
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mmol) as colorless crystals: mp 115-117°C; IR (CHC13) 3420, 1720, 1600, 1335, 1140 cm-l; 1H
NMR (CDC13, 300 MHz) 8 8.14 (d, J = 9.0 Hz, 2H), 7.53 (d, J = 9.0 Hz, 2H), 7.45 (d, J = 8.7
Hz, 2H), 7.25 (d, J = 8.7 Hz, 2H), 6.53 (dt, J = 5.7, 15.9 Hz, 1H), 6.47 (d, J = 15.8 Hz, 1H),
3.58 (d, J = 5.7 Hz, 2H). Anal. Calcd for C 17H1 3F 3N 20 3 : C, 58.29; H, 3.74; N, 8.00. Found:
C, 58.38; H, 3.80; N, 7.83.
3-[4- (Trifluoroacetyl)amino]phenyl]-1-(4-nitrophenyl)-1,2-(E)-epoxypropane
(55). A mixture of 54 (996.1 mg, 2.76 mmol) and m-CPBA (1.19 g, 5.52 mmol) in CH2C12
(40 mL) was heated at reflux under an argon atmosphere for 24 h. After being cooled to room
temperature, the solution was washed with saturated aqueous NaHCO3 (20 mL) and brine (20
mL), and the combined organic layers were dried over MgSO4 and concentrated. The residue was
purified by flash chromatography (silica gel, 50/50 hexane/Et20O) to provide 55 (918 mg, 2.73
mmol) in 99% yield as colorless crystals: mp 126-128 °C; IR (CHC13) 3420, 1730, 1600, 1340,
1140 cm-1; 1H NMR (CDC13, 300 MHz) 8 8.17 (d, J = 8.7 Hz, 2H), 7.85 (brs, 1H), 7.53 (d, J =
8.7 Hz, 2H), 7.39 (d, J = 8.7 Hz, 2H), 7.30 (d, J = 8.7 Hz, 2H), 3.74 (d, J = 1.8 Hz, 1H), 3.15
(ddd, J = 1.8, 4.2, 5.7 Hz, 1H), 3.11 (dd, J = 4.2, 14.6 Hz, 1H), 3.00 (dd, J = 5.7, 14.6 Hz,
1H). Anal. Calcd for C 17H 13 F 3N 2 04: C, 55.74; H, 3.58; N, 7.64. Found: C, 55.88; H, 3.56;
N, 7.53.
3- [4- [(5-Methoxy-1,5- dioxo p en t yl)amino]phenyl-1-(4-nitrophenyl)-1,2-(E)-
epoxypropane (56). To a solution of 55 (1.00 g, 2.73 mmol) in EtOH (25 mL) was added
sodium borohydride (513 mg, 13.5 mmol) at 0 C, and the mixture was stirred for 1 h. The
reaction was quenched by addition of acetic acid, and the resulting white precipitate was removed
by filtration. The filtrate was concentrated under reduced pressure, and the residue was diluted
with EtOAc. The solution was washed with saturated aqueous NaHC03 (10 mL) and brine (10
mL), dried over MgSO4, and concentrated. The crude residue was dissolved in CH2C12 (20 mL),
and to this solution was added triethylamine (0.46 mL, 2.37 mmol) followed by 5-methoxy-5-
oxopentanoyl chloride (641 mg, 2.73 mmol) at room temperature with stirring. After 30 min, the
solution was washed with saturated aqueous NaHCO3 (10 mL) and brine (10 mL), dried
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(MgSO4), and concentrated. The residue was crystallized from 50/50 CHC13/hexane to afford 56
in 84% yield (910 mg, 2.28 mmol) as colorless crystals: mp 133-135 C; IR (CHC13) 3420,
1730, 1600, 1340, 1140 cm-1; 1H NMR (CDC13, 300 MHz) 8 8.16 (d, J = 8.4 Hz, 2H), 7.47 (d,
J = 8.4 Hz, 2H), 7.38 (d, J = 8.4 Hz, 2H), 7.36 (brs, 1H), 7.21 (d, J = 8.4 Hz, 2H), 3.72 (d, J
= 1.8 Hz, 1H), 3.67 (s, 3H), 3.12 (dt, J = 1.8, 5.7 Hz, 1H), 2.99 (d, J = 5,7 Hz, 2H), 2.43 (t, J
= 7.2 Hz, 2H), 2.41 (t, J = 7.2 Hz, 2H), 2.03 (quint, J = 7.2 Hz, 2H). Anal. Calcd for
C2 1H 2 2N 2 06: C, 63.31; H, 5.57; N, 7.03. Found: C, 63.26; H, 5.43; N, 6.96.
3- [4- [(5-Methoxy- 1,5-dioxopentyl)amino]phenyl]- 1-(4-nitrophenyl)- 1-
azidopropan-2-ol (57a). The mixture of 56 (892 mg, 2.24 mmol), sodium azide (1.46 g,
22.4 mmol), and NH4C1 (1.23 g, 23.0 mmol) in acetone/water (20 mL/10 mL) was heated at 70°C
for 48 h. The acetone was removed on a rotary evaporator, and the resulting aqueous residue was
extracted with EtOAc (3 x 10 mL). The extracts were washed with saturated aqueous NaHC03 (5
mL) and brine (5 mL), and the combined organic layers were dried over MgSO4 and concentrated.
Purification of the residue by chromatography (silica gel, 50/50 hexane/EtOAc) provided 57a in
89% yield (878 mg, 1.99 mmol) as a yellow oil: IR (CHC13) 3430, 2950, 1720, 1680, 1590,
1340 cm-1; 1H NMR (CDC13, 300 MHz) 8 8.21 (d, J = 9.0 Hz, 2H), 7.69 (s, 1H), 7.53 (d, J =
9.0 Hz, 2H), 7.37 (d, J = 8.4 Hz, 2H), 7.06 (d, J = 8.4 Hz, 2H), 4.61 (d, J = 6.0 Hz, 1H), 3.99
(m, 1H), 3.63 (s, 3H), 2.74 (dd, J = 3.3, 13.8 Hz, 1H), 2.90 (dd, J = 9.0, 13.8 Hz, 1H), 2.49
(brs, 1H), 2.37 (t, J = 7.5 Hz, 2H), 2.34 (t, J = 7.5 Hz, 2H), 1.96 (quin, J = 7.5 Hz, 2H);
HRMS [M]+ calcd 441.1648, found 441.1645.
3- [4- [(5-Methoxy- 1,5-dioxopentyl)amino]phenyl]-2- [(triethylsilyl)oxy]- 1-(4-
nitrophenyl)propyl azide (57b). To a solution of 57a (316 mg, 0.716 mmol) and 2,6-
lutidine (108 gL, 0.931 mmol) in CH 2 C12 (8 mL) at -78 °C was added triethylsilyl
trifluoromethanesulfonate (194 gL, 0.859 mmol) with stirring, and the mixture was allowed to
warm to room temperature over a 4 h period. The solution was washed with saturated aqueous
NaHCO3 (5 mL) followed by brine (5 mL), and the combined organic layers were dried over
MgSO4 and concentrated. The residue was purified by column chromatography (silica gel, 70/30
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hexane/EtOAc) to afford 57b in 99% yield (395 mg, 0.71 mmol) as a yellow oil: IR (CHC13)
3540, 3420, 2940, 2080, 1720, 1680, 1590, 1340 cm-1; 1H NMR (CDC13, 300 MHz) 8 8.19 (d,
J = 8.7 Hz, 2H), 7.66 (brs, 1H), 7.48 (d, J = 8.7 Hz, 2H), 7.42 (d, J = 8.7 Hz, 2H), 7.01 (d, J
= 8.7 Hz, 2H), 4.45 (d, J = 4.5 Hz, 1H), 4.13 (ddd, J = 4.5, 4.8, 6.9 Hz, 1H), 3.65 (s, 3H),
2.75 (dd, J = 6.9, 14.1 Hz, 1H), 2.52 (dd, J = 4.8, 14.1 Hz, 1H), 2.41 (t, J = 7.5 Hz, 2H), 2.40
(t, J = 7.5 Hz, 2H), 2.01 (quint, J = 7.5 Hz, 2H), 0.83 (t, J = 8.0 Hz, 9H), 0.39 (q, J = 8.0 Hz,
6H).
3- [4- [(5-Methoxy- 1,5-dioxopentyl)amino] phenyl]-2- [(triethylsilyl)oxy]- 1-(4-
nitrophenyl)-N,N-dimethylpropylamine (57c). A solution of 57b (395 mg, 0.710
mmol) and triphenylphosphine (223 mg, 0.852 mmol) in THF (5 mL) was stirred 2 days at room
temperature, and to this was added water (19 gpL, 1.06 mmol). After stirring another 2 days, the
solvent was removed under reduced pressure, and the residue was passed through a short column
of silica gel (50/50 hexane/EtOAc) to give the corresponding amine contaminated with
triphenylphosphine oxide. To the product, dissolved in acetonitrile (5 mL), was added 37%
paraformaldehyde in water (0.6 mL, 7.0 mmol) with stirring. After 10 min, sodium
cyanoborohydride (352 mg, 5.60 mmol) was added at room temperature, and the suspension was
stirred for 2 h. The reaction was quenched by addition of acetic acid, and the volatile solvents
were removed on a rotary evaporator. The residue was diluted with EtOAc (10 mL), and the
solution was washed with saturated aqueous NaHCO3 (5 mL) followed by brine (5 mL), dried
(MgSO4), and concentrated. The residue was purified by column chromatography (silica gel,
50/50 hexane/EtOAc) to provide 57c (198 mg, 0.354 mmol) as a yellow oil. The total yield from
57b was 51%: 1H NMR (CDC13, 300 MHz) 8 8.14 (d, J = 9.0 Hz, 2H), 7.43 (d, J = 9.0 Hz,
2H), 7.40 (d, J = 8.7 Hz, 2H), 7.06 (d, J = 8.7 Hz, 2H), 4.42 (q, J = 5.4 Hz, 1H), 3.65 (s, 3H),
3.11 (d, J = 5.4 Hz, 1H), 2.70 (ABq, J = 5.4 Hz, 1H), 2.42 (t, J = 7.5 Hz, 2H), 2.41 (t, J = 7.5
Hz, 2H), 2.08 (s, 6H), 2.01 (quint, J = 7.5 Hz, 2H), 0.78 (t, J = 7.8 Hz, 9H), 0.37 (q, J = 7.8
Hz, 6H); HRMS [M]+ calcd 558.1999, found 558.1996.
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3-[4-[(5-Methoxy-1,5-dioxopentyl)aminol phenyl]- 1- (4-nitrophenyl)-2-hydroxy-
N,N-dimethylpropylamine (58a). To a solution of 57c (150 mg, 0.268 mmol) in
acetonitrile (5 mL) was added 1.1 mL of 5% hydrogen fluoride in acetonitrile/water (85/15) at
room temperature, and the mixture was stirred overnight. The resulting solution was neutralized
by addition of saturated aqueous NaHCO3 (2 mL), and the volatile solvents were removed on a
rotary evaporator. The aqueous residue was extracted with EtOAc (3 x 3 mL), and the combined
extracts were washed with brine (3 mL). The organic layers were dried over MgSO4 and
concentrated, and the residue was chromatographed (silica gel, EtOAc) to afford 58a in 100%
yield (118 mg, 0.268 mmol): IR (CHC13) 3430, 2950, 2780, 1720, 1680, 1590, 1340 cm-1 ; 1H
NMR (CDC13, 300 MHz) § 8.17 (d, J = 8.7 Hz, 2H), 8.72 (brs, 1H), 7.42 (d, J = 8.7 Hz, 2H),
7.38 (d, J = 8.4 Hz, 2H), 7.04 (d, J = 8.4 Hz, 2H), 4.34 (dt, J = 4.0, 8.7 Hz, 1H), 3.63 (s, 3H),
3.11 (d, J = 4.5 Hz, 1H), 2.7 (brs, 1H), 2.48 (dd, J = 3.9, 13.8 Hz, 1H), 2.38 (t, J = 7.5 Hz,
2H), 2.35 (t, J = 7.5 Hz, 2H), 2.24 (dd, J = 8.7, 13.8 Hz, 1H), 2.18 (s, 6H), 1.98 (quint, J =
7.5 Hz, 2H); HRMS [MOCH 3]+ calcd 412.1872, found 412.1875.
3- [4- [[5- [(2,5-Dioxo-1-pyrrolidinyl)oxy]- 1,5-dioxopentyllamino] phenyl]-2-
hydroxy-1-(4-nitrophenyl)-N,N-dimethylpropylamine (58b). A solution of 58a (20
mg, 0.045 mmol) and lithium hydroxide monohydrate (4.0 mg, 0.09 mmol) in t-BuOH (0.6 mL)
and H 20 (0.3 mL) was stirred 24 h at room temperature, and the solvents were removed by freeze
drying. The residue was extracted with EtOAc (5 mL), and the extract, after filtration, was
concentrated under reduced pressure. The residue was dissolved in CH2C12 (3 mL), and to this
solution was added EDC (13.4 mg, 0.070 mmol) and N-hydroxysuccinimide (9.2 mg, 0.080
mmol) at room temperature. After stirring 3 h, the insoluble materials were filtered off and washed
with CH2C12 (3 mL), and the combined filtrates were washed with brine (3 x 2 mL). The
combined organic layers were dried over MgSO4 and concentrated to provide 58b in 67% yield
(16 mg, 0.030 mmol) as a yellow oil. The product was used for the next step without further
purification: IR (CH 2C12) 3430, 2950, 2780, 1820, 1790, 1740, 1680, 1590, 1340 cm-1 ; 1H
NMR (CDC13, 300 MHz) 8.17 (d, J = 8.1 Hz, 2H), 8.02 (s, 1H), 7.47 (d, J = 8.1 Hz, 2H),
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7.41 (d, J = 8.4 Hz, 2H), 7.04 (d, J = 8.4 Hz, 2H), 4.35 (dt, J = 4.5, 8.4 Hz, 1H), 3.11 (d, J =
4.5 Hz, 1H), 2.84 (brs, 4H), 2.67 (t, J = 6.9 Hz, 2H), 2.48 (dd, J = 3.9, 14.0 Hz, 1H), 2.41 (t,
J = 6.9 Hz, 2H), 2.24 (dd, J = 5.4, 14.0 Hz, 1H), 2.19 (s, 6H), 2.13 (quint, J = 6.9 Hz, 2H).
[3- [4- [[5- [(2,5-Dioxo- 1-pyrrolidinyl)oxy]- 1,5-dioxopentyl]amino] phenyl]-2-
hydroxy-1-(4-nitrophenyl)propyl]trimethylammonium iodide (H5a). To a solution
of 57b (16 mg, 0.030 mmol) in acetone (1 mL) was added methyl iodide (19 gL, 0.030 mmol) at
room temperature, and the mixture was stirred overnight. The solvent was removed on a rotary
evaporator, and the residue was vigorously stirred with CH2C12 (1 mL) for 5 min. A yellow
viscous oil remained undissolved and was isolated by decantation (8.5 mg, 0.017 mmol, 42%
yield). 1H NMR (in acetone-d6) analysis demonstrated that the oil H5a was >90% purity, and the
product was used for conjugation with carrier proteins without further purification: mp 225-230
°C (dec); 1H NMR (acetone-D6, 300 MHz) 8 9.11 (s, 1H), 8.48 (d, J = 7.8 Hz, 1H), 8.34 (d, J
= 7.8 Hz, 1H), 8.30 (d, J = 8.4 Hz, 1H), 7.93 (d, J = 8.4 Hz, 1H), 7.45 (d, J = 8.7 Hz, 2H),
7.05 (d, J = 8.7 Hz, 2H), 5.47 (brs, 1H), 5.08 (brm, 1H), 3.44 (s, 9H), 2.83 (s, 4H), 2.68 (t, J
= 8.4 Hz, 2H), 2.58 (dd, J = 3.9, 16.0 Hz, 1H), 2.48 (t, J = 8.4 Hz, 2H), 2.39 (dd, J = 5.4,
16.0 Hz, 1H), 2.05 (quint, J = 8.4 Hz, 2H); 1H NMR (D 20, 300 MHz) 6 8.14-8.30 (m, 3H),
7.77 (s, 1H), 7.45 (d, J = 7.8 Hz, 1H), 7.19 (d, J = 8.1 Hz, 2H), 6.96 (d, J = 8.1 Hz, 2H), 4.88
(dt, J = 1.5, 5.7 Hz, 1H), 4.25 (d, J = 1.5 Hz, 1H), 3.05 (s, 9H), 2.78 (s, 4H), 2.68 (t, J = 7.2
Hz, 2H), 2.48-2.22 (m, 2H), 2.39 (t, J = 7.2 Hz, 2H), 1.95 (quint, J = 7.2 Hz, 2H).
5.1.2. Synthesis of Hapten H6a
3-(4-Aminophenyl)-l-(4-nitrophenyl)-l-azidopropan-2-ol (62). A solution of 55
(500 mg, 1.37 mmol), sodium azide (910 mg, 14.0 mmol), and NH4Cl (249 mg, 14.0 mmol) in
acetone/water (10 mL/5 mL) was heated at 70 C for 48 h. The acetone was removed under
reduced pressure, and the resulting aqueous residue was dissolved in MeOH (5 mL) and water (5
mL). After the addition of K2C03 (553 mg, 4.00 mmol), the orange solution was stirred at room
temperature overnight. The methanol was removed on a rotary evaporator, and the aqueous
residue was extracted with EtOAc (3 x 5 mL). The organic extracts were washed with brine (5
71
mL), dried over MgSO4, and concentrated. Purification of the residue by chromatography (silica
gel, 50/50 hexane/EtOAc) provided 62 in 62% yield (264 mg, 0.84 mmol) as orange crystals: mp
137-139 C; IR (CHC13) 3540, 3400, 2090, 1600, 1340 cm- 1; 1H NMR (CDC13, 300 MHz) 6
8.24 (d, J = 8.4 Hz, 2H), 7.56 (d, J = 8.4 Hz, 2H), 6.94 (d, J = 8.4 Hz, 2H), 6.63 (d, J = 8.4
Hz, 2H), 4.63 (d, J = 5.4 Hz, 1H), 4.00 (ddd, J = 4.2, 5.4, 9.0 Hz, 1H), 3.6 (brs, 1H), 2.71
(dd, J = 4.2, 13.8 Hz, 1H), 2.56 (dd, J = 9.0, 13.8 Hz, 1H), 1.7 (brs, 2H). Anal. Calcd for
C 1 5H 15N503: C, 57.50; H, 4.83; N, 22.35. Found: C, 57.65; H, 4.90; N, 22.18.
3,3'-Dithiodipropionic Acid, Bis[ [4- [3- (4-nitro)phenyl-3-azido-2-
hydroxypropyl]phenyl]amide] (63). A solution of 62 (264 mg, 0.844 mmol) and 3,3'-
dithiodipropionic acid, bissuccinimidoester (155 mg, 0.348 mmol) in CH2C12 (15 mL) was heated
at reflux for 48 h, and the resulting solution was washed with brine (2 x 5 mL). The organic
layers were combined, dried over MgSO4, and concentrated under reduced pressure. The residue
was purified by column chromatography (silica gel, 40/60 hexane/EtOAc) to afford 63 in 55%
yield (170 mg, 0.212 mmol) as a yellow amorphous solid: mp 75-80 °C (dec); IR (CHC13) 3540,
3420, 2090, 1740, 1345, 1600, 1340 cm-1; 1H NMR (CDC13, 300 MHz) 6 8.13 (d, J = 8.7 Hz,
2H), 7.48 (d, J = 8.7 Hz, 2H), 7.34 (d, J = 8.4 Hz, 2H), 6.99 (d, J = 8.4 Hz, 2H), 4.54 (d, J =
5.7 Hz, 1H), 3.99 (ddd, J = 5.3, 6.3, 8.7 Hz, 1H), 2.98 (dd, J = 6.3, 9.5 Hz, 1H), 2.94 (t, J =
6.6 Hz, 2H), 2.76 (s, 1H), 2.65 (t, J = 6.6 Hz, 2H) 2.54 (dd, J = 8.7, 9.5 Hz, 1H).
3,3'-Dithiodipropionic Acid, Bis [ [4- [3 -(4-nitrophenyl)-3-amino-2-
hydroxypropyl]phenyl]amide] (dithio-H6a). A solution of 63 (49.4 mg, 0.0617 mmol)
and triphenylphosphine (38.5 mg, 0.145 mmol) in THF (3 mL) was stirred 2 days at room
temperature, and to this was added water (3.6 pL, 0.20 mmol). After stirring another 2 days, the
solvent was removed under reduced pressure, and the residue was passed through a short column
of silca gel (EtOAc) to provide dithio-H6a in 70% yield (32.3 mg, 0.0432 mmol) as a yellow oil:
IR (CHC13) 3420, 3300, 2920, 1670, 1600, 1340 cm-1; 1H NMR (CDC13, 300 MHz) 6 8.09 (d, J
= 8.7 Hz, 2H), 7.48 (d, J = 8.7 Hz, 2H), 7.30 (d, J = 8.4 Hz, 2H), 7.14 (d, J = 8.4 Hz, 2H),
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3.03 (t, J = 6.6 Hz, 2H), 2.91 (d, J = 5.4 Hz, 1H), 2.80 (d, J = 2.7 Hz, 1H), 2.73 (t, J = 6.6
Hz, 2H), 2.26 (dt, J = 2.7, 5.4 Hz, 1H), 1.65 (brs, 2H).
3- [4-(3-Mercapto-l-oxopropenyl)amino] phenyl]- 1- (4-nitrophenyl)- 1-
aminopropan-2-ol (H6a). To a solution of dithio-H6a (26.0 mg, 0.0347 mmol) and a
catalytic amount of triethylamine (1.4 L, 0.014 mmol) in CH2 C12 (1.5 mL) was added
dithioerythritol (5.9 mg, 0.0382 mmol) at room temperature, and the mixture was stirred 4 h. The
volatile material was removed under reduced pressure, and the residue was chromatographed
(silica gel, EtOAc) to furnish H6a in 77% yield (20.0 mg, 0.0533 mmol) as a yellow oil: IR
(CHC13) 3420, 2920, 2680, 1590, 1510, 1340 cm- 1; H NMR (CDC13, 300 MHz) 8 8.13 (d, J =
8.4 Hz, 2H), 7.48 (d, J = 8.4 Hz, 2H), 7.33 (d, J = 8.4 Hz, 2H), 7.21 (d, J = 8.4 Hz, 2H), 2.96
(ABq, J = 5.4 Hz, 2H), 2.88 (dt, J = 6.5, 8.4 Hz, 1H), 2.81 (d, J = 2.4 Hz, 1H), 2.67 (t, J = 6.5
Hz, 2H), 2.77 (brm, 1H), 1.69 (t, J = 8.4 Hz, 1H), 1.5 (br s, 3H).
5.1.3. Synthesis of Hapten H7a
3-[4-[(5-Methoxy-1,5-dioxopentyl)amino]phenyl]-2-(O,O-dimethylphosphoryl)- 1-
(4-nitrophenyl)propyl azide (64). To a solution of 56 (120 mg, 0.27 mmol) and dimethyl
N,N'-diethyl phosphoramidate (89 pL, 0.49 mmol) in THF (5mL) was added 1H-tetrazole (114
mg, 1.36 mmol) at room temperature under an argon atmosphere. The mixture was stirred for 15
min and then cooled to -78 °C, and to this was added a solution of m-CPBA (99 mg, 0.49 mmol)
in CH2C12 (6 mL). After 10 min, 5% aqueous KHSO4 (14 mL) was added, and the mixture was
stirred 10 min. The organic layer was washed with saturated aqueous NaHCO3 (5 mL) and brine
(5 mL) and dried over Na2SO4. The concentrated residue was purified by column chromatography
(silica gel, 25/75 hexane/EtOAc) to provide 64 in 80% yield (120 mg, 0.216 mol) as a colorless
oil: IR (CH2 C12) 3430, 2100, 1730, 1690, 1595, 1515, 1345 cm-1; 1H NMR (CDC13, 300 MHz)
8 8.22 (d, J = 8.8 Hz, 2H), 7.61 (d, J = 8.5 Hz, 2H), 7.43 (d, J = 8.5 Hz, 2H), 7.07 (d, J = 8.5
Hz, 2H), 5.08 (d, J = 4.6 Hz, 1H), 4.79 (m, 1H), 3.59 (s, 3H), 3.56 (d, J = 11.3 Hz, 3H), 3.34
(d, J = 11.3 Hz, 3H), 3.02 (m, 1H), 2.81 (m, 1H), 2.37 (t, J = 7.5 Hz, 2H), 2.34 (t, J = 7.4 Hz,
2H), 1.96 (quint, J = 7.5 Hz, 2H); 3 1p NMR (CDC13, 60 MHz) 8 -4.01.
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3- [4- [(5-Methoxy-1,5-dioxopentyl)amino] phenyl]-2-(O,O-dimethylphosphoryl)- 1-
(4-nitrophenyl)-N,N-dimethylpropylamine (65). To a solution of 64 (410 mg, 0.75
mmol) in methanol (7 mL) was added propane-1,3-dithiol (262 jpL, 2.61 mmol) and triethylamine
(364 gL, 2.61 mmol) at room temperature, and the mixture was stirred 20 h. The resulting
solution was concentrated under reduced pressure, and the residue was purified by column
chromatography (silica gel, 50/50 CHC13/EtOH followed by EtOH) to afford an oily residue. The
residue was dissolved in acetonitrile (10 mL), and to this was added 37% paraformaldehyde in
water (650 pL, 7.5 mmol). The mixture was stirred for 20 min, NaCNBH3 (377 mg, 5.99 mmol)
was added, and the resulting solution was vigorously stirred 2 h at room temperature. The reaction
was then quenched by the addition of glacial acetic acid (1 mL) and allowed to stir for another 20
min. The resulting mixture was diluted with EtOAc (10 mL) and washed with saturated aqueous
NaHCO3 (5 mL) followed by brine (5 mL), and the organic layer was dried over MgSO4 and
concentrated. The residue was chromatographed on silica gel (EtOAc) to furnish 65 (183 mg,
0.338 mmol). The total yield from 64 was 45%: IR (CH2C12) 3420, 2940, 1730, 1690, 1595,
1515, 1405, 1345 cm-l1; 1H NMR (CDC13, 300 MHz) 8 8.18 (d, J = 8.7 Hz, 2H), 7.53 (s, 1H),
7.46 (d, J = 8.4 Hz, 2H), 7.40 (d, J = 8.7 Hz, 2H), 7.22 (d, J = 8.1 Hz, 2H), 5.21 (m, 1H),
3.67 (s, 3H), 3.51 (d, J = 11.2 Hz), 3.34 (m, 1H), 3.32 (d, J = 11.2 Hz, 3H), 3.03 (m, 2H),
2.34 (m, 4H), 2.11 (s, 6H), 2.03 (m, 2H); 31 p NMR (CDC13, 60 MHz) 8 -22.5.
3- [4- [[5- [(2,5-Dioxo-l-pyrrolidinyl)oxy]- 1,5-dioxopentyl]amino] phenyl]-2-(O,O-
dimethylphosphoryl)-l-(4-nitrophenyl)-N,N-dimethylpropylamine (66). To a
solution of 65 (99 mg, 0.18 mmol) in t-BuOH (2 mL) and water (1.5 mL) was added lithium
hydroxide monohydrate (16 mg, 0.36 mmol), and the mixture was stirred 5 h at room temperature.
The resulting solution was concentrated under reduced pressure, and the residue was passed
through a short column (silica gel) eluting with EtOH to provide a yellow oil. This oil was stirred
with EDC (51 mg, 0.27 mmol) and N-hydroxysuccinimide (39 mg, 0.32 mmol) in CH2 C12 (7 mL)
for 12 h at room temperature, and the resulting solution was washed with brine (5 mL), dried over
MgSO4, and concentrated. The resulting residue was purified by column chromatography (silica
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gel, EtOH) to afford 66 (74 mg, 0.234 mmol) as a yellow solid. The total yield from 65 was
65%: mp 78-80 °C; IR (CH2C12) 3420, 3370, 2940, 1820, 1790, 1740, 1590, 1600, 1515, 1345
cm-1; 1H NMR (CDC13, 300 MHz) 6 8.33 (s, 1H), 8.13 (d, J = 8.5 Hz, 2H), 7.45 (d, J = 8.5
Hz, 2H), 7.36 (d, J 8.5 Hz, 2H), 7.16 (d, J = 8.2 Hz, 2H), 5.15 (m, 1H), 3.44 (d, J = 11.3 Hz,
3H), 3.30 (d, J = 11.2 Hz, 3H), 2.98 (m, 2H), 2.80 (brs, 4H), 2.65 (t, J = 6.9 Hz, 2H), 2.41 (t,
J = 6.9 Hz, 2H), 2.11 (quint, J = 6.9 Hz, 2H), 2.07 (s, 6H); 31 p NMR (CDC13) 6 -22.5.
[3- [4- [[5- [(2,5-Dioxo-1-pyrrolidinyl)oxy]-1,5- dioxopentylamino] phenyl]-2-
phosphoryl-1-(4-nitrophenyl)propyl]trimethylammonium iodide (H7a). To a
solution of 66 (16 mg, 0.025 mmol) in acetone (1 mL) was added methyl iodide (16 gL, 0.025
mmol) at room temperature, and additional 32 gL portions (0.05 mmol) of the same reagent were
added each day for 6 days. At day 7 the solvent was removed on a rotary evaporator, and the
residue was vigorously stirred with CH2C12 (1 ml) for 5 min. The CH2C12 solution was decanted,
and the remaining insoluble yellow viscous oil was dissolved in acetonitrile (1 mL). To this was
added trimethylsilyl iodide (13 iL) at 0 °C, and the mixture was stirred 2 h. The solvent was
removed under reduced pressure to afford H7a in 44% yield (7.0 mg, 0.11 mmol) as a colorless
solid. The product was used for conjugation with carrier proteins without further purification: mp
217-222 C (dec); 1H NMR (CD30D, 250 MHz) 8 8.38 (m, 2H), 8.25 (brd, 2H), 7.55 (brd, 2H),
7.50 (d, J = 8.4 Hz, 2H), 7.03 (d, J = 8.4 Hz), 5.57 (m, 1H), 4.45 (brs, 1H), 3.34 (m, 1H),
3.23 (s, 9H), 2.84 (brs, 4H), 2.75 (t, J = 8.4 Hz, 2H), 2.52 (t, J = 8.4 Hz, 2H), 2.48 (m, 1H),
2.12 (quint, J = 8.4 Hz, 2H); 31 p NMR (CD 30D) 6 -0.27.
5.2. Generation of Monoclonal Antibody
5.2.1. Preparation of Antigen
Hapten H6a (2-4 mg) was dissolved in 0.25 mL of DMF and diluted with 0.25 mL of
water. The resulting solution was slowly added to a solution of maleimide-BSA or maleimide-
Fib9 c (-5 mg) in 0.5 mL of 0.2 M potassium phosphate buffer (KPi) at pH 7.2, and the mixture
was gently stirred 2 h at room temperature. The resulting solution (BSA-H6) or suspension (Fib-
H6) was dialyzed twice against KPi (1 L) at 4 °C. The concentration of BSA-1 was determined
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by Bradford analysis (2-4 mg/mL of the conjugate was generally obtained), and the number of
hapten molecules per BSA was estimated to be more than 10 molecules by measuring the
absorbance at 250 nm (max of H6a). The BSA-H6 conjugate was used for ELISA experiments,
and the suspension of the conjugate Fib-H6 was used for immunization (assuming that it contained
-5 mg/mL of protein).
The protein-hapten conjugates of H5a, H2a, and H7a were prepared in a similar manner.
To a solution of the hapten (2-4 mg) in KPi (0.5 mL) was slowly added a solution of BSA or Fib
(5 mg) in KPi (5 mL), and the mixture was stirred 2 h at room temperature. After dialysis of the
mixture against KPi, its concentration (3-5 mg/mL) and number of hapten molecules per protein
(>10 hapten molecules/protein) were determined in the same manner as described above, and the
BSA-hapten and the Fib-hapten conjugates were used for immunization and ELISA, respectively.
5.2.2. Antibody Production and Purification
Four Balb/c mice each received a subcutaneous injection of 100 gg of the appropriate
protein-hapten conjugate emulsified in RIBI adjuvant (MPL and TDM emulsion) on days 1 and 14
(boost #1). On day 21, serum was taken from the animals, and the titer was determined by
ELISA. On day 35, the mouse with the highest titer received a second subcutaneous boost (boost
#2) with the same protein-hapten conjugate.
Three days after the last boost (boost #2), the spleen was taken from the animal and the
cells were fused with 5 x10 7 653/HGPRT myeloma cells to prepare hybridomas. Cells were
plated into six 96-well cell culture plates; each well containing 100 AL of HAT-DMEM
(hypoxanthine, aminopterin, thymidine-Dulbecco's minimal essential medium) with 20% of fetal
bovine serum and 1% of hybridoma enhancing supplement (Sigma). After 2 weeks, the plates
were analyzed by ELISA for binding to the appropriate protein-hapten conjugate, and all colonies
that displayed tight binding were subcloned two or three times to produce monoclonal cell lines.
Each of these cell lines were individually injected into pristane-primed Balb/c mice to generate
ascitic fluid. The harvested ascitic fluid was treated with a saturated ammonium sulfate solution
76
(AS) to give a final concentration of 45% AS, and the precipitated antibodies were dissolved in and
dialyzed against 50 mM Tris-HCl, pH 7.8.
Antibodies (IgG) were purified by DEAE-Sephacel anion-exchange chromatography (salt
gradient from 0 mM to 500 mM NaCi in 50 mM Tris-HC1, pH 7.8) and protein G-Sepharose
affinity chromatography (antibodies were loaded on in 20 mM potassium phosphate, pH 7.2 and
eluted with 100 mM glycine°HC1, pH 2.7). The purity of the final antibody solution was greater
than 95% by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis.
5.2.3. Antibody Affinity Measurement
An ELISA was performed to identify positive hybridoma clones producing IgG molecules
which specifically bind to the hapten. Each well of a 96-well polyvinyl assay plate (ELISA plate)
was coated with 100 L of the appropriate protein-hapten conjugate (2 gg/mL) in 50 mM Na2CO3
(pH 9.0) and incubated at 4 *C overnight or at room temperature for 2 h. The plate was washed
with phosphate buffer salt (PBS, 10 mM, pH 7.2 phosphate, 150 mM NaCl) containing 5 %
Tween 20 (PBS Tween) three times followed by water (washing protocol). The hybridoma
supernatant from each well of the 96-well cell culture plates was added to the ELISA plates and
incubated for 1 h, the supernatant was removed, and the plates were washed according to the
washing protocol. A solution of goat anti-mouse IgG-horseradish peroxidase (Bio-Rad) in PBS
Tween was added to each well, the plates were incubated for 1 h, and the washing protocol was
repeated. Finally, each well was treated with 100 FL of a solution of 1,2-phenylenediamine (0.4
mg/mL) in 0.1 M sodium citrate (pH 5.0) containing 0.1 % hydrogen peroxide, the yellow color
was allowed to develop for approximately 5 min, and the addition of 20 pL of 1.0 M H2S0 4 was
used to end the reaction. Positive clones were identified by measuring the absorbance at 450 nm
using a microtiter plate reader or more simply by visual identification through comparison with the
negative controls.
Titration of antibodies in animal serum was carried out as follows. The protein-hapten
coated ELISA plate was prepared as described above, and to each well was added 100 AL of PBS.
The serum was diluted 200-fold in PBS, and 100 gL was added to the first well (Al) of the plate.
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The resulting solution was serially diluted 2-fold from well Al to well A8 (from 1:400 to 1:51 200
dilution), and the plate was incubated for 1 h. The ELISA procedure was then applied as described
above, and the absorbance at 450 nm was measured. A plot of the log of the serum dilution vs
absorbance provided a sigmoidal curve, and the titer was defined as the serum dilution at which the
absorbance became comparable to that of the background.
A competition ELISA protocol was followed to determine dissociation constants (Kds) of
inhibitors (haptens H2b and HSb-H7b, substrates SE and SA, PNP, and the product acid) for
each antibody. Prior to carrying out the competition ELISA, the optimum antibody concentration
and the incubation time on the ELISA plate (pre coated with 2 gg/mL of the protein-hapten
conjugate and then blocked with BSA) were determined to establish a reproducible titration curve.
This is critical for detecting a weak antibody affinity to an inhibitor. The minimum antibody
concentration is defined as the concentration at which ca. 70% of the antibody (reflecting on the
absorbance) binds to protein-hapten conjugate. In our experiments, the concentration and the
incubation time were generally in the range of 0.25-1.0 gg/mL and 10-20 min, respectively.
Competition ELISA experiments were performed as follows. A 60 p.L solution of each inhibitor
(in 50 mM Tris*HC1, 80 gM NaC1, pH 7.8) was serially diluted 2-fold across a BSA-blocked
ELISA plate (from well Al to well A12), containing 60 pL of buffer per well. To each well was
then added 60 gL of an antibody solution (the final concentration was preadjusted) and the mixture
was equilibrated for 30 min at 25'C. The resulting antibody-inhibitor solution (100 L) from each
well was transferred to the corresponding well of the ELISA plate with a multipipeter and
incubated for the preadjusted time (10-20 min). After washing the plate, the ELISA protocol was
followed and a titration curve (the sigmoidal plot of the log of the antibody concentration vs
absorbance) was obtained. The results were analyzed by a Klotz plot (a double reciprocal plot of
the inhibitor concentration vs the ratio of inhibitor-bound antibody to the total added antibody), the
slope of the line yielding the Kd for the inhibitor. All assays were repeated three times.
5.3. Kinetic Measurements
5.3.1. General Methods
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Each purified monoclonal antibody solution was dialyzed against the assay buffer, and the
concentration was determined by measurement of the absorbance at 280 nm. Assays were
performed in a microtiter plate reader (Bio-Tek Instruments) equipped with the Delta Soft II
computer program (Biometalics, Inc.). All assays were performed at least in duplicate.
5.3.2. Determination of Extinction Coefficiencies of p-Nitrophenol
Absorbence (405 nm) of p-nitrophenol at each pH was measured with five different
concentrations (12.5, 25, 50, 100, 250 mM), and the linear slope corresponding to the extinction
coefficiency was obtained by plotting the concentration vs. its absorbance. The obtained extinction
coefficiencies were as follows:
pH 6.2:1.65 x 103 ODoM- 1 (50 mM Mes, 80gM NaCl)
pH 6.6: 2.94 x 103 OD-M- 1 (50 mM Pipes, 80gM NaCl)
pH 7.0: 4.64 x 103 OD-M- 1 (50 mM Pipes, 80gM NaCl)
pH 7.2: 5.51 x 103 OD*M-1 (50 mM Hepes or 50mM Tris-HCl, 80gM NaCl)
pH 7.4: 6.52 x 103 OD-M- 1 (50 mM Hepes or 50mM Tris-HCl, 80gM NaCl)
pH 7.8: 8.11 x 103 OD*M-1 (50 mM Hepes or 50mM Tris*HCl, 80gM NaCl)
pH 8.2: 8.88 x 103 OD°M- 1 (50 mM Ches, 80gM NaC1)
pH 8.5: 9.30 x 103 OD-M- 1 (50 mM Ches, 80gM NaC1)
The extinction coefficiencies in three component buffer MHD (12.5 mM Mes, 12.5 mM
Hepes, 25 mM diethanolamine) at each pH were as follows:
pH 6.2: 1.44 x 103 OD*M-1
pH 6.4: 2.32 x 103 OD*M-1
pH 6.6: 2.80 x 103 OD*M-1
pH 6.8: 3.44 x 103 OD°M- 1
pH 7.0: 4.64 x 103 OD-M-1
pH 7.2: 6.12 x 103 OD°M -1
pH 7.4: 6.60 x 103 OD°M -1
pH 7.8: 8.28 x 103 OD*M-1
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pH 8.2: 8.84 x 103 OD.M - 1
pH 8.5: 9.14 x 103 ODoM-1
5.3.3. Determination of Background Hydrolysis Rate Constants
Background hydrolysis rate constants (kun) of ester in the buffer at each pH were
determined by extrapolation to the zero-buffer concentration. The rate at five variable
concentrations of buffer species from 10 mM to 50 mM (fixed NaCI concentration with 80 tRM
containing 5 % organic cosolvents) was determined by measuring the absorbance change at 405
nm corresponding to p-nitrophenolate release. The linear line of the plot (rate vs. concentration of
buffer species) was extrapolated to zero-buffer concentration to obtain the background hydrolysis
rate constant (kun). The obtained rate constants were as follows:
pH 6.2: 5.00 x 10-5 min -l (Mes, 80pM NaCl)
pH 6.6: 7.41 x 10-5 min-1 (Pipes, 80pM NaCl)
pH 7.0: 1.84 x 10 4 min- (Pipes, 80gM NaCl)
pH 7.2: 1.85 x 10-4 min-1 (Hepes or Tris.HCl, 80pM NaCl)
pH 7.4: 1.97 x 10 -4 min-l (Hepes or Tris-HCl, 80gM NaCl)
pH 7.8: 5.13 x 10 -4 min-l (Hepes or Tris-HCl, 80gM NaCl)
pH 8.2: 9.08 x 1 0 -4 min -1 (Ches, 80jM NaCl)
pH 8.5: 1.50 x 10-3 min-1 (Ches, 80pM NaCl)
The background hydrolysis rate constants (kun.obs) of ester in the 50 mM buffer at each pH
were determined as follows:
pH 6.2: 9.4 x 10-5 min-1 (50 mM Mes, 80gM NaCl)
pH 6.6: 2.3 x 10-5 min-I (50 mM Pipes, 80ptM NaCi)
pH 7.0: 4.6 x 10-4 min- (50 mM Pipes, 80pM NaCl)
pH 7.2: 7.9 x 10 -4 min-1 (50 mM Hepes or 50mM Tris*HCl, 80p.M NaCl)
pH 7.4: 1.2 x 10-3 min-1 (50 mM Hepes or 50mM Tris-HCl, 80pM NaCl)
pH 7.8: 2.0 x 10-3 min-1 (50 mM Hepes or 50mM Tris-HCl, 80gM NaCl)
pH 8.2: 8.9 x 10-3 min-1 (50 mM Ches, 80gM NaCl)
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pH 8.5: 1.3 x 10-2 min- 1 (50 mM Ches, 80tM NaCl)
5.3.4. Catalytic Assays of Antibodies
Initial screening for catalysis by antibodies was performed at 25 °C in buffer solution (50
mM Mes, 80 gM NaCl, pH 6.2, or 50 mM Tris*HC1, 80 F.M NaCI, pH 7.8) with 5 % of organic
cosolvents (4.8% acetonitrile and 0.2% dimethyl sulfoxide), containing 1.0 mM ester SE and 10
gIM antibody. The rates were determined by measuring the initial change in linear absorbance at
405 nm reflecting on p-nitrophenolate release. The background hydrolysis rate of the substrate (in
the absence of antibody) was also measured each time. Antibodies found to be capable of
catalyzing the hydrolysis were further studied.
The antibody-catalyzed hydrolysis rates of ester SE in the presence of 0.5-10 pM antibody
were measured as a function of substrate concentration under the conditions used in the
aforementioned screening. The substrate concentration was varied from 0.25 to 3.0 mM (the
solubility limit of SE) to obtain eight data points, and the observed rates were corrected for the
uncatalyzed rate of hydrolysis (in the absence of antibody). The corrected rates were analyzed by a
Lineweaver-Burk plot to determine the Michaelis-Menten parameters (kcat and Km).
Inhibition constants (Ki) were determined in the standard fashion. The antibody-catalyzed
hydrolysis rates as a function of both the inhibitor concentration (fixed substrate concentration) and
the substrate concentration in the presence of a fixed concentration of inhibitor were measured at
pH 7.8 to provide a Dixon plot and a Lineweaver-Burk plot, respectively. Analyses of these
afforded Ki values of the respective inhibitors for the antibodies.
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Appendix I
Protocols
Preparation of Hapten-protein Conjugate.
I. Conjugation of water-soluble hapten with carrier protein.
Materials:
Hapten (2-4mg)
Carrier protein (5mg of BSA, Fibrinogen, KLH)
Potassium phosphate KPi (0.2M, pH7.2)
Vial with magnet stirring bar
Magnetic stirrer
Dialysis tube
Filtering apparatus (lOmL syringe and 0.22gm disposable filter)
Bradford assay solution (BIO-RAD) diluted 4-fold with ionized water
Method:
1. Dissolve 2-4mg of hapten bearing an activated ester in 0.5mL of KPi at room temperature
(occasionally warm to dissolve).
2. Dissolve 5mg of a carrier protein in 0.5 mL of KPi.
3. Add slowly the solution of hapten to the solution of carrier protein with swirling.
4. Gently stir with a stirring bar on a magnetic stirrer for 2h at room temperature.
5. Transfer the solution to a dialysis tube, and dialyze in 1L of KPi over night at 4'C.
6. Filter to remove precipitated materials, and measure its UV absorbance.
7. Determine the concentration of the protein conjugate by using Bradford assay (by comparison
with a known concentration of protein), and estimate the amount of haptens on the carrier
protein.
II. Conjugation of water-insoluble hapten with carrier protein.
Materials:
Same materials as I
DMF
NAP-5 (size-exclusion column, Pharmacia#17-0853-02)
Method:
1. Dissolve 2-4mg of hapten in 0.25mL of DMF. Add carefully 0.25mL of KPi to the DMF
solution.
2. Dissolve 5mg of a carrier protein in 0.5 mL of KPi.
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3. Add slowly the solution of hapten to the solution of carrier protein with swirling. If
precipitation were observed, add more DMF to dissolve the precipitation (upto 50% of DMF can
be capable).
4. Gently stir with a stirring bar on a magnetic stirrer for 2h at room temperature.
5. Prepare NAP-5 to equilibrate with 20% DMF in KPi.
6. Load the reaction mixture on NAP-5, and collect lmL of each fraction.
7. Take 5M of each fraction into 0.5mL of Bradford solution, and obtain the fractions that
correspond to protein (color of the solution changes from pale red to blue)
8. Transfer the solution containing protein to a dialysis tube, and dialyze twice in 1L of KPi at
4°C.
9. Filter to remove precipitated materials, and measure its UV absorbance.
10. Determine the concentration of the protein conjugate by using Bradford assay (by
comparison with a known concentration of protein), and estimate the amount of haptens on the
carrier protein.
Immunization.
I. Preparation of antigen solution.
Materials:
Hapten-protein conjugate solution in KPi (the concentration is known)
PBS (sterilized)
RIBI adjuvant (BIBI Immunochem Research Inc.)
Method:
1. Take the solution containing lmg of hapten-protein conjugate, and dilute with PBS to give a
final volume of 2mL (0.5mg/mL).
2. Add the solution to a bottle of RIBI adjuvant, and vortex for 2min.
3. Store at 4°C.
II. Immunization.
Materials:
Antigen emulsion with RIBI adjuvant
lmL syringe with 25-g needle
Method:
1. Just prior to use, vortex the antigen emulsion for 2min.
2. Take lmL of the antigen emulsion into lmL syringe with 25-g needle.
3. Inject 200gL to each mouse subcutaneously. Each mouse receives 100l g of hapten-protein
conjugate.
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4. At day 14 from the primary injection, repeat 1-3. Secondary injection can be done
subcutaneously or intraperitoneally.
5. 7days after the second injection, bleed to obtain serum and examine the titration of antibodies.
See ELISA section.
6. More than three weeks after the second injection, the selected mouse can subcutaneously or
intraperitoneally receive 200gL of antigen emulsion, and the spleen is harvested to generate
hybridomas.
Preparation of Medium.
I. Preparation of Supplement.
Materials:
dd Water (Filtered and sterilized ionized water)
Oxaloacetic acid, sodium salt (Sigma #07753)
Pyruvic acid, sodium salt (Sigma #P5280)
Insulin (Sigma #I4011)
Glutamine (Sigma #G5763)
Gentamicin (Sigma #G1522)
Filter (0.22ptm, Millex-GS)
Syringe (50mL and 10mL)
50mL and 10 mL centrifuge bottle
Method:
Preparation O.P.
1. Dissolve 1.5g of oxaloacetic acid and 0.5g of pyruvic acid in 100mL of dd water.
2. Adjust to pH7.4, and filter by using 100mL syringe to sterilize.
3. Store 40mL each in 50mL centrifuge bottle at -20°C.
Preparation of insulin
4. Dissolve 50mg of insulin in 10mL of 1.OM HC1, and filter by using 10mL syringe to sterilize.
5. Store 10 mL in 10mL centrifuge bottle at 4°C.
Preparation of glutamine
6. Prepare 200mM solution and filter by using 50mL syringe to sterilize.
7. Store 40mL each in 50mL centrifuge bottle at -20°C.
Preparation of gentamicin
8. Filter by using 10mL syringe to sterilize, and store in 10mL centrifuge bottle at 4°C.
II. Preparation of DME Medium.
Materials:
DME base medium (Sigma #9161), 1L
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O.P., 10mL
Glutamine, 20mL
Insulin, lmL
Gentamicin, lmL
Method:
1. Just prior to make medium, combine all materials into DME base medium.
2. Store at 4°C after making the medium.
III. Preparation of medium with supplements.
Materials:
DME medium
FBS (Fetal Bovine Serum, Sigma #F4010)
HES (Hybridoma Enhancing Supplement, Sigma #H8142)
8-Azaguanine (Sigma #A5284)
HAT supplement (Hypoxanthine, Aminopterine and Thymidine, Sigma #H0262)
ECGS (Endothelial Cell Growth Supplement, Collaborative Research #40006)
Method:
Medium M: DME medium containing 8-azaguanine and 5% FBS
1. Add 50mL of FBS to DME medium.
2. Add 10mL of the medium to the bottle of 8-Azaguanine and suspend to dissolve. The
concentration should be 6.6 x 10-3 M.
3. Transfer the solution to 10mL centrifuge bottle to store at -200C.
4. Make medium containing approximately 2 x 10-5 M of 8-azaguanine. For example, add 3mL
of 8-azaguanine solution to 1L of 5% FBS DME medium.
5. Store at 4°C.
Medium I: Serum-free DME medium containing ECGS
1. Add 10mL of DME medium to bottle of ECGS, and suspend to dissolve.
2. Transfer the solution of ECGS to the original medium.
3. Store at 4'C.
Medium II: HAT-DME medium containing 20% FBS. ECGS. 1% HES
1. Add 10mL of DME medium to bottle of HAT, and suspend to dissolve.
2. Transfer the solution of HAT to the original medium.
3. Add 10mL of the HAT-DME medium to bottle of ECGS, and suspend to dissolve.
4. Transfer the resulting solution of ECGS to the original HAT-DME medium.
5. Add 200mL of FBS and 10mL of HES to the medium and suspend.
6. Store at 40C.
Medium III: DME medium containing 20% FBS. 1% HES
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1. Add 200mL of FBS and 10mL of HES to DME medium and suspend.
2. Store at 4°C.
Preparation of Myeloma Cell.
I. Preparation and selection of Myeloma cells.
Materials:
DME medium containing 5% FBS and 8-azaguanine (medium M)
50mL centrifuge bottle
24-wells plate
lOmL culture flask
Method:
1. Warm medium M at 370C, and prepare 25 mL of medium M in 50mL centrifuge bottle.
2. Thaw frozen myeloma cells in a 37°C water bath, and transfer the cells into 25 mL of medium
M as quick as possible.
3. Suspend the cells and spin at 1300rpm for 5min. Remove the medium, and loosen the pellet.
4. Add 25mL of medium M. Repeat 3.
5. Add 10 mL of medium M and suspend, and transfer to 10 mL culture flask.
6. Calculate the volume of the medium containing approximately 102 cells.
7. Prepare 24-wells plate containing 2mL of medium M in the first well and lmL in the rest of
wells.
8. Transfer the medium containing approximately 103 cells into the first well of 24-wells plate,
suspend cells, and then transfer lmL to the next well. In the same manner, serially dilute 2-fold
until 24th well. In theory, the 9th-l0th well should contain one cell.
9. Place both culture flasks at 370C in a C0 2 incubator.
10. Clones should be visible by microscope at about day 7. Most diluted healthy cells in 24-
wells plate can be transfer to 10mL followed by 50mL of culture flask to obtain 5 x 107 cells
with greater than 95% of viability.
IL. Preparation of Frozen Myeloma cells.
Materials:
FBS
DMSO
Myeloma cells (107 cells)
50mL centrifuge bottle
Vial (for freezing) x4
Method:
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1. Prepare 95% FBS and 5% DMSO by volume. It can be stored at -20C over a period of one
year.
2. Count viable myeloma cells and determine the volume of medium containing approximately
107 cells. Greater than 95% of the viability has to be obtain.
3. Transfer the cells to 50mL centrifuge bottle, and spin at 1300rpm for 5min.
4. Remove the medium as much as possible, and loosen the pellet.
5. Add mL of 95% FBS and 5% DMSO, and gently suspend.
6. Transfer 0.25mL for each vial, and put the vials on an ice as rapid as possible.
7. Place the vials at -78°C in a freezer. After a couple of days , two vials can be transfer to liquid
nitrogen storage tank.
Determination of Viable Cells.
Materials:
Microscope
Trypan blue (Sigma #8154)
Microscope reading plate
Micropipette
Method:
1. Suspend cells in the culture flask by using a sterilized pipette.
2. Take lmL or less of the cells to a culture tube.
3. Transfer 20pL or more of the cells by a micropipette to another culture tube, and add an
equivalent volume of trypan blue to the tube.
4. Suspend the mixture, and put on a microscope reading plate.
5. Count viable cells, which are clear (non-viable cells are blue), in one of the 9 squares.
6. Take average number of the viable cells, and multiply with 2 x 104 to give the concentration
(cells/mL). For example, if 25 cells are observed in the square, 25 x 2 x104 = 5 x 105 cells/mL
are the concentration of viable cells in the culture flask.
Generation of Hybridomas.
I. Feeder Medium.
Materials:
Adult (retired) mice x2
Serum-free DME medium containing ECGS (medium I)
HAT DME medium containing 20% FBS, ECGS, 1% HES (medium II)
Razor blade
Glass slide
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50mL centrifuge bottle
10mL culture flask x2
Method:
Preparation of feeder medium has to be done one day before fusion.
1. Warm 25mL of medium I at 37°C in 50mL centrifuge bottle, and warm medium I and medium
II at 370C.
2. Sacrifice two adult mice and harvest their spleen to transfer into prewarmed 25mL of medium
I.
3. Under clean bench hood, carefully remove the supernatant medium and add 25mL of medium
I to wash the spleens.
4. Add 10mL of medium I to petri dish, and transfer the spleen to this.
5. Cut the spleen four pieces by a razor blade, and gently grind them by using glass slides
washing with the medium.
6. Transfer cells into 50mL centrifuge bottle, and top to 25mL with medium I and suspend cells.
7. Spin at 1300rpm for 5min, and carefully remove the medium without disturbing cells.
8. Loosen the pellet and resuspend cells in 25 mL of medium I. Repeat 7.
9. Loosen the pellet and resuspend cells in 20 mL of medium II.
10. Leave for min (large fats sit on the bottom), and transfer cells to 10mL culture flask (x2).
11. Place one day at 370C in a C02 incubator.
12. At the day of fusion, transfer the medium to 50mL centrifuge bottle, and spin at 1300rpm for
5min.
13. Dilute the supernatant medium with medium II to give 50mL of final volume of the feeder
medium.
II. Fusion.
Materials:
Serum-free DME medium containing ECGS (medium I)
HAT DME medium containing 20% FBS, ECGS, 1% HES (medium II)
Myeloma cells (5 x 107)
PEG (Bohermger-Mannhaim, #783641 PEG 1500)
Razor blade
Glass slide
96-wells plate (sterilized with lid) x8
50 mL centrifuge bottle
Multi-pipette
Method:
Preparation of suspension of spleen cells and mveloma cells:
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1. Warm 25mL of medium I at 37°C in 50mL centrifuge bottle, and warm medium I and medium
II at 37°C.
2. Sacrifice selected immunized mouse and harvest the spleen to transfer into prewarmed 25mL
of medium I.
3. Under clean bench hood, carefully remove the medium and add 25mL of medium I to wash
the spleen.
4. Add 10mL of medium I to petri dish, and transfer the spleen to this.
5. Cut the spleen four pieces by a razor blade, and gently grind them by using glass slides
washing with the medium.
6. Transfer cells into 50mL centrifuge bottle, and top to 25mL with medium I and suspend cells.
Meanwhile, prepare 5 x 107 of myeloma cells and transfer into 50 mL centrifuge bottle.
7. Spin at 1300rpm for 5min, and carefully remove the supernatant medium without disturbing
cells. Warm PEG at 370C.
8. Loosen the pellet and resuspend cells in 25 mL of medium I. Repeat 7.
9. Loosen the pellet and resuspend cells in 25 mL of medium I. Combine the cell suspensions
into one bottle, and gently suspend together.
10. Spin the combined cells at 1900rpm for 5min, and carefully remove the medium as complete
as possible and loosen the pellet.
Fusion:
11. Add prewarmed mL PEG to the pellet with gently swirling over a period of min at room
temperature.
12. Immerse tube in a 37°C water bath for 90sec with constant swirling.
13. Add mL of medium I at room temperature over a period of 30sec, 3mL over 30sec, and 20
mL over lmin to stop fusion.
14. Top to 40mL with medium I and leave for 10 min at room temperature.
15. Centrifuge at 1300rpm for 10 min, and remove the supernatant medium.
16. Loosen the pellet, and gently resuspend the cells in 25mL of medium II.
17. Transfer cells into 50 mL of feeder medium and well suspend them.
18. Transfer cells to petri dish, and dispense lOO1L of cells into wells of 8 96-well plate using
multi-pipette.
19. Place the plates at 37°C in a CO2 incubator.
20. Clones should be visible by microscope at about day 7. Feed 100AtL of medium II.
Note: When visible colonies by eye are formed (usually at day 14), ELISA can be done. When
the positive colonies become confluent or more than 10 4/mL viable cells are observed by
microscope, they can be transferred to 24-wells (lmL) and, meanwhile, can be subcloned by a
limiting dilution.
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Limiting Dilution.
I. 1st Limiting Dilution (1-dimensional protocol).
Materials:
DME medium containing 20% FBS, 1% HES (medium III)
96-wells plate (sterilized with lid)
Multi-pipette
Method:
1. Count viable cells by microscope and calculate the volume of the medium containing
approximately 102 cells. For example, if 5 x 104 cells/mL is observed, 2L of medium contains
approximately 102 cells.
2. Prepare 96-wells plate containing 200pL of medium III in the first column (A1-Hl) wells and
lOO1 L in the rest of the wells.
3. Gently suspend each cell-line in the positive well and transfer approximately 102 cells into the
first well (Al) of the each lane.
4. Suspend the medium of the first well by using a multi-pipette, then transfer lOO1L to the
second well, and serially dilute 2-fold 12 times from Al to A12. In theory, the 6th-8th (A6-A8)
well contains one cell.
5. Place the plates at 37°C in a C02 incubator.
6. Clones should be visible by microscope at about day 7. Feed 100L of medium III.
7. When visible colonies by eye are formed (usually at day 14), ELISA can be done. When
positive colonies in the most diluted well become confluent or more than 104/mL viable cells are
observed by microscope, they can be transferred to 24-wells (lmL) and, meanwhile, can be
subcloned by 2nd limiting dilution.
II. 2nd Limiting Dilution (2-dimensional protocol).
Materials:
DME medium containing 20% FBS, 1% HES (medium III)
96-wells plate (sterilized with lid)
Multi-pipette
Method:
1. Count viable cells by microscope and calculate the volume of the medium containing
approximately 103 cells. For example, if 5 x 104 cells/mL is observed, 20gL of medium contains
approximately 103 cells.
2. Prepare 3-set of petri dish containing 10mL of medium III.
3. Gently suspend the cells in the most diluted positive well and transfer approximately 103 cells
into the lOmL of medium on the petri dish.
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4. Suspend the medium and transfer 100lL into the first 2 columns (Al-H1 and A2-H2) of the
96-wells plate by using a multi-pipette. In theory, each well contains 10 cells/well.
5. Transfer lmL of the previous petri dish medium (102 cells/mL) into 10mL of medium on the
second petri dish. Suspend the medium and transfer 100lL into the next 4 columns (from A3-H3
to A6-H6) of the 96-wells plate. In theory, each well contains approximately 1 cells/well.
6. Transfer 3mL of the second petri dish medium (10 cells/mL) into 10mL of medium on the last
petri dish. Suspend the medium and transfer lOO1L into the next 6 columns (from A7-H7 to
A12-H12) of the 96-wells plate. In theory, each well contains approximately 0.3 cells/well.
7. Place the plates at 37'C in a CO2 incubator.
8. Clones should be visible by microscope at about day 7. Carefully observe monoclonarity of
the forming colony, and notify if it is so. Feed lOO1L of medium III.
9. When visible colonies by eye are formed (usually at day 14), ELISA can be done. If the
positive colony is consistent with the observed monoclonarity, it can be monoclone with a high
chance. When positive colonies in most diluted well become confluent, the cells can be
transferred to 24-wells plate (lmL).
10. In order to confirm the monoclonarity, repeat the limiting dilution to observe that all wells
forming colonies are positive by ELISA (none of well containing colonies are negative).
ELISA (Enzyme-Linked ImmunoSorbent Assay).
I. General Procedure.
Materials:
Hapten-protein (fibrinogen or BSA) conjugate
96-wells plate (flexible vinyl, Coster #2595)
0.05M NaCO3 (pH9.0)
PBS
Blocking PBS containing lOg/mL of protein (fibrinogen or BSA)
Washing PBS containing tween 20 (1:1000 dilution)
Goat anti-mouse IgG-HRP conjugate (BIO-RAD, #170-6516)
0.1M Sodium citrate (pH5.0)
1,2-Phenylenediamine (Aldrich, 98% grade)
Hydrogen peroxide (30% wt)
1.OM H2SO4
Method:
1. Coat the wells of 96-wells plate with antigen by placing 100RL of the hapten-protein
conjugate solution in 0.05M NaCO3 (1-2 gg/mL) and incubating at 4°C overnight or at room
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temperature for 2 hours. If the conjugate is not stable at basic pH, PBS can be used instead of
0.05M NaCO3.
2. Remove the antigen solution and block by adding 200pL of the blocking PBS and incubating
at 37 0C for 1 hour.
3. Remove the blocking solution and wash 3 times with 200gL of the washing PBS. Wash with
water and dry.
4. Add 100pL of antibody solution to each antigen-coated well on the plate and incubate at room
temperature for 1 hour.
5. Remove the antibody solution and wash 3 times with the washing PBS and water.
6. Prepare goat anti-mouse IgG-HRP conjugate in washing PBS (1:1000 dilution). Add 100gL
to each well and incubate for 1 hour.
7. Remove the solution and wash 3 times with washing PBS and water.
8. Just prior use, prepare substrate (1,2-phenylenediamine) solution in 0.1M sodium citrate
(4mg/10mL) and vigorously stir, and then add hydrogen peroxide (lgpL/10mL, 1:10,000 dilution)
followed by stirring.
9. Add the prepared substrate solution to each well and incubate at room temperature for 5 min in
dark.
10. Stop the reaction by adding 20pL of 1.OM H2S04 to the above solution.
11. Read results by the microtiter plate reader at 450nm.
II. Titration of Serum Antibodies.
Material:
Serum from mouse
Carrier protein used for immunization (positive control)
Carrier protein not used for immunization (negative control)
Other materials are same as above
Method:
1. Sit collected blood at room temperature for 30min, and then spin with 4000 rpm for 20min.
2. Take 50JL of the top clear layer corresponding to serum and dilute with 950gL of PBS (1:200
dilution).
3. Prepare the plate coated with hapten-(screening)protein conjugate, carrier protein (positive
control), and carrier (screening)protein (negative control).
4. Add 100pL of PBS to each antigen coated well on the plate.
5. Add 100BpL of the serum solution to the first well containing 100pL of PBS, and serially dilute
2-fold 8-times from Al to H1 (from 1:400 to 1:51200 dilution).
6. Incubate at room temperature for 1 hour.
7. Follow the general procedure (6-11).
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8. Analyze the titration curve (4-parameter plot by Delta soft computer program) to obtain the
titer.
III. Competition ELISA.*
Materials:
Purified antibody solution (known concentration) or supernatant of cell culture (unknown
concentration)
Assay buffer or PBS
Inhibitor solution
Other materials are same as above
Method:
Calibration of the hapten-protein conjugate concentration. antibody concentration. and time
period of incubation:
1. Prepare plate coated with 4, 2, and lg/mL of hapten-protein conjugate (four different time
periods of incubation will be calibrated by one plate), and prepare plate coated with blocking
PBS.
2. Prepare 7.5Rg/mL of antibody solution or supernatant of cell culture.
3. Add 120pL of assay buffer or PBS to each well coated with the blocking PBS.
4. Add 120pL of antibody solution to the first well, and serially dilute 2-fold 8-times from Al to
H1 (from 3.75ptg/mL to 0.0146gg/mL).
5. Transfer 100pL of each antibody solution to the corresponding well coated with the hapten-
protein conjugate, and incubate for 60min, 45 min, 30min, and 15min.
6. Remove the solution and wash 3 times with 200pL of washing PBS, and follow the general
procedure (6-11).
7. Analyze the titration curve. Determine minimum concentration of hapten-protein conjugate
and minimum time for incubation (normally 15 min) providing a nice titration curve. Obtain the
antibody concentrations where 70% of antibody bound to hapten (plate).
Competition ELISA:
8. Prepare plate coated with the calibrated concentration of hapten-protein conjugate, and prepare
plate coated with blocking PBS.
9. Add 60pL of assay buffer or PBS to each well coated with the blocking PBS.
10. Add 60gL of inhibitor solution to the first well, and serially diluted 2-fold 12-times from Al
to A12 (from 1:2 to 1:2048 dilution).
11. Add 60gL of the calibrated concentration of antibody to each well, and incubate at room
temperature for 30 min. Note. The final concentration of inhibitor should be from 1:4 to 1:4096
dilution of the original concentration. The adding antibody solution has to be 2-fold
concentrated solution of the calibrated concentration.
97
12. Transfer 100pL of the mixture of antibody and inhibitor to the corresponding well coated
with the hapten-protein conjugate, and incubate at room temperature for the calibrated time
period.
13. Remove the solution and wash 3 times with 200pL of washing PBS, and follow the general
procedure (6-11).
14. Analyze the titration curve. Determine the inhibitor concentration v.s. the ratio of inhibitor-
bound antibody over total antibody added, and plot the double reciprocal number (Klotz plot) to
obtain the linear slope that corresponds to the inhibitor dissociation constant.
*B. Friguet, A.F. Chaffotte, C. Dijaudi-ohaniance, M.E. Goldberg, Immunol. Methods. 77, 305
(1985).
Large Scale Production of Monoclonal Antibody and Its Purification.
I. Ascites Production From Monoclonal Hybridomas.
Materials:
Pristane (0.5mL per mouse)
PBS (0.5mL per mouse)
Hybridoma cells (minimum 106 per mouse)
ImL syringe with 25-g needle (for hybridoma cells injection)
18-g needle and tube for fluid collection
Method:
Pretreatment:
1. At least 7 days before cell injection, inject 0.5mL of pristane by using lmL syringe with 25-g
needle into adult or retired mice by intraperitoneal injection (i.p.).
Cell injection:
2. Each of monoclonal cell lines was grown to a high density in 60mL of media (1-5 x10 5
cells/mL) in cell culture. The healthily growing hybridoma cells (minimum 106 cells: ideally 107
cells) were pelleted down at 1000 rpm, 5 min and the supernatant discarded.
3. Resuspend pellet in 0.5 mL of sterile PBS and inject i.p.
Fluid collection:
4. Within two weeks* abdominal swelling will be observed. Hold the mouse as for i.p. injections
and carefully insert 18-g needle into the peritoneal cavity from the side of the animal about 1/4 of
inch deep until fluid comes out. At this point the needle can be removed and fluid can be
collected by gently squeezing.
5. Collect fluid drops into 15 mL (or 50 mL) tube. 2-5 mL of fluid should be obtained.
6. After a couple of days fluid could be collected again depending on the level of swelling.
While larger swelling signifies larger volume of ascites fluid, it can also kill the animal.
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8. After 3 collections the animal should be killed, according to MIT regulations.
*If the swelling has not be observed, repeat cell-injection several times. If it has not be still
observed, the cell line must be re-cloned to obtain healthy cells.
II. Preliminary Purification of Ascitic Fluid.
Materials:
Saturated ammonium sulfate (SAS) cooled at 4'C
Ascitic fluid (freshly collected)
Centrifuge tube
50mM TrisoHCl (adjusted to pH 7.8)
Method:
1. Spin freshly collected ascitic fluid at 4000 rpm, and separate the supernatant from red blood.
2. Add equal volume of SAS dropwise under vigorously stirring and stand at 4°C for at least 30
min. The samples can be stored for short periods (upto a few days) at this stage.
3. Centrifuge at 8000 rpm, 20 min, 4'C, and gently wash the precipitate with 50% AS (do not
resuspend) and discard the supernatant.
4. Keep the precipitate over 1-2 mL of 50mM Tris*HCl at 4°C, and store the solution at -20°C
until further purification.
III. Purification of mAb: DEAE Ion-exchange Chromatography.
Materials:
DEAE column
Dialysis tube
Filtering apparatus (lOmL syringe and 0.45gm disposable filter)
Centrifuge tube
50mM Tris*HCl (adjusted to pH 7.8)
50mM Tris*HCl, 500mM NaCl
Pharmacia FPLC (placed in the cold room)
Culture tube
Method:
Preparation of DEAE column:
1. Equilibrate DEAE sephacel beads (Pharmacia cat#17-0500-03) with 50mM Tris-HCl to get rid
of EtOH in which the beads are stored.
2. Pour 20 mL of the beads into Pharmacia column XK26/20 (cat#18-1000-72). 10 mL of beads
is generally capable for 100 mg of total proteins.
3. Pass 50mM TrisoHCl through the column several times to prepare column for purification.
Preparation samples:
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4. Dialyze the solution of mAb (from step4, part II) against 50mM Tris.HCl at 4°C. Change the
buffer at least twice.
5. Centrifuge at 13000 rpm for 10 min to remove any insoluble materials.
6. filter the aliquot through 0.45gm filter with a syringe into 50mL tube.
FPLC:
7. Set DEAE column in FPLC, and equilibrate the column with 50mM Tris*HCl. The running
method is programmed in NO.7 file (see the list of program, Figure 7). The program is run by
three-step gradient starting from OmM NaCl (45mL) to 50mM (40mL), 150mM (80mL), 500mM
NaCl(40mL), and equilibrated to OmM NaCl (50mL).
8. Apply all of sample (10-15mL) to the column, and monitor the absorbance at 280nm (the
sensitivity of the monitor must be set at 2.0).
9. Collect the fractions (10mL each) of the corresponding to Ab* and store at 4°C.
* The representative OD-profiles are shown (Figure 7). mAb is contained in the fractions of the
first and the second peaks (the second peak is moved depending on the sample) according to
SDS-PAGE gel analyses. It has been also confirmed by protein-G purification.
IV. Concentration of mAb solution.
Materials:
Amicon filtration apparatus (200mL volume cell model 8200, cat#5123; membrane
YM30, cat#13732)
Magnetic stirrer
Nitrogen gas (for pressure)
Method:
1. Set up Amicon filtration apparatus connected to nitrogen gas cylinder in the cold room.
2. Pour mAb solution into the cell.
3. Purge nitrogen gas at 40psi into cell under gently stirring.
4. The solution is concentrated to 5-10mL (it usually takes 30-60min). Collect the concentrated
solution into 15mL tube and stored at 4°C (or directly dialyze against 20mM KPi, see V).
V. Purification of IgG: Protein-G Affinity Chromatography.
Materials:
Protein-G column* (Pharmacia, Protein-G Superrose HR16/5, cat#17-0682-01)
* Protein-G superose contains 10mL of gel and has a total binding capacity of 50mg IgG
(515mg IgG/mL gel) at a flow rate of 2mL/min.
Dialysis tube
Centrifuge tube
Filtering apparatus (10mL syringe and 0.22gm disposable filter)
20mM Potassium phosphate KPi (adjusted to pH7.2)
100
100mM GlycinoHCl (adjusted to pH2.7)
1M Tris-HCl (adjusted to pH9)
Pharmacia FPLC (placed in the cold room)
Culture tube
Method:
Preparation of samples:
1. Dialyze the solution of mAb against 20mM KPi at 4'C. Change the buffer at least twice.
2. Centrifuge at 13000 rpm for 10min to remove any insoluble materials.
3. filter the aliquot through 0.22gm filter with a syringe into 50mL tube.
FPLC:
4. Set Protein-G column in FPLC and equilibrate with 20mM KPi (to get rid of EtOH in which
the gel is stored). The running method is programmed in NO.3 file (see the list of program,
Figure 8). The program is run by 20mM KPi (120mL), 100mM Glycin*HCl (120mL), and
equilibrated to KPi (60mL).
5. Add 200pL* 1 of Tris°HCl into the tube of fraction 20-30.
6. Apply 10-30 mL of the sample in 20mM KPi to the column, and monitor the absorbance at
280nm (the sensitivity of the monitor must be set at 1.0).
7. Collect the fractions (6mL each) of the corresponding to IgG which are usually in the fraction
between 22 and 26.
8. Check pH of the combined IgG solution to make sure it is pH7. Add 1M NaN3 to be 0.1% of
the total volume of IgG solution.
9. Store at 4'C. It should be stable for a year under this condition.
10. Recover the fraction of 1-10. These fractions often contain IgG, and another injection to
Protein-G column may provide a substantial amount of IgG.
*1 The actual amount of Tris.HCl added must be adjust to give a pH7 when 6mL of 100mM
Glycin*HCl is added to a tube.
*2 Representative OD-profiles are shown (Figure 8).
VI. Quantification of IgG.
Method:
1. Prepare 1:20 dilution of purified IgG (50gL of IgG solution in 950pL of 20mM KPi).
2. Read the absorbance at 280nm by spectrophotometer, and calculate the IgG concentration by
the following equation:
IgG (mg/mL) = OD280nm x 20 x 1/1.35
1.35: an extinction coefficiency of pure IgG
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